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Background: The aim of fistula surgery is to eradicate the disease while preserving anal sphincter
function. The efficacy of the Surgisis® anal fistula plug (Cook Medical, Bloomington, IN, USA) in the
treatment of trans-sphincteric fistula-in-ano has been variably reported.
Objectives: To undertake a randomised comparison of the safety and efficacy of the Surgisis anal fistula
plug in comparison with surgeon’s preference for the treatment of trans-sphincteric anal fistulas.
Design: A randomised, unblinded, parallel-arm, prospective, multicentre clinical trial.
Setting: Hospitals in the UK NHS involving colorectal surgeons accredited by the Association of
Coloproctology of Great Britain and Ireland.
Participants: Adult patients suffering from trans-sphincteric fistula-in-ano of cryptoglandular origin.
Interventions: Patients were randomised on a 1 : 1 basis to either the fistula plug or the surgeon’s preference
[e.g. fistulotomy, cutting seton, advancement flap or ligation of intersphincteric fistula tract (LIFT) procedure].
Main outcome measures: The primary outcome measure was quality of life as measured by the Faecal
Incontinence Quality of Life (FIQoL) questionnaire at 12-month follow-up. Secondary outcome measures
included clinical and radiological fistula healing rates, faecal incontinence rates, complications rates,
reintervention rates and cost-effectiveness.
Results: Between May 2011 and March 2016, 304 participants were recruited (152 fistula plug vs.
152 surgeon’s preference). No difference in FIQoL score between the two trial groups was seen at the
6-week, 6-month or 12-month follow-up. Clinical evidence of fistula healing was reported in 66 of 122 (54%)
participants in the fistula plug group and in 66 of 119 (55%) participants in the surgeon’s preference group
at 12 months. Magnetic resonance imaging (MRI) showed fistula healing in 54 of 110 (49%) participants in
the fistula plug group and in 63 of 112 (56%) participants in the surgeon’s preference group. Variation in
12-month clinical healing rates was observed: 55%, 64%, 75%, 53% and 42% for fistula plug, cutting
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seton, fistulotomy, advancement flap and LIFT procedure, respectively. Faecal incontinence rates were low at
baseline, with small improvement in both groups post treatment. Complications and reinterventions were
frequent. The mean total costs were £2738 [standard deviation (SD) £1151] in the fistula plug group and
£2308 (SD £1228) in the surgeon’s preference group. The average total quality-adjusted life-years (QALYs)
gain was much smaller in the fistula plug group (0.829, SD 0.174) than in the surgeon’s preference group
(0.790, SD 0.212). Using multiple imputation and probabilistic sensitivity analysis, and adjusting for differences
in baseline EuroQol-5 Dimensions, three-level version utility, there was a 35–45% chance that the fistula plug
was as cost-effective as surgeon’s preference over a range of thresholds of willingness to pay for a single
QALY of £20,000–30,000.
Limitations: Limitations include a smaller sample size than originally calculated, a lack of blinding that
perhaps biased patient-reported outcomes and a lower compliance rate with MRI at 12-month follow-up.
Conclusions: The Surgisis anal fistula plug is associated with similar FIQoL score to surgeon’s preference at
12-month follow-up. The higher costs and highly uncertain and small gains in QALYs associated with the
fistula plug mean that this technology is unlikely to be considered a cost-effective use of resources in the
UK NHS.
Future work: Further in-depth analysis should consider the clinical and MRI characteristics of fistula-in-ano
in an attempt to identify predictors of fistula response to treatment.
Trial registration: Current Controlled Trials ISRCTN78352529.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 21.
See the NIHR Journals Library website for further project information.
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Plain English summary
F istula-in-ano is a common condition in which the inside of the anus is in communication with theoutside skin. It is a cause of long-term suffering owing to recurrent infection. Many surgical operations
have been proposed to treat fistula-in-ano, with varying degrees of success. These carry the risk of faecal
incontinence. The aim of the Fistula-In-Ano Trial (FIAT) was to assess the benefits of a new technology, the
Surgisis® anal fistula plug (Cook Medical, Bloomington, IN, USA), compared with other surgical techniques.
The FIAT involved 304 participants; 152 participants were treated with the fistula plug and 152 participants
were treated with an alternative surgical technique. There were no differences in quality of life (QoL) among
participants treated with the fistula plug compared with those receiving other treatments when assessed
12 months following the operation. Successful fistula healing was achieved in 54% of fistula plug-treated
participants and in 55% of participants treated with an alternative technique at 12 months following the
operation. Few patients suffered from faecal incontinence before their operation and there was a slight
improvement following treatment with the fistula plug and other surgical treatments. The only difference
seen between the group treated with the fistula plug and those receiving other surgical treatments was in
the complication rate at the 6-week assessment time, with the fistula plug group having higher rates of
unexpected pain.
Economic analysis of the fistula plug compared with the other surgical treatments showed that the fistula
plug was more expensive and only produced very small improvements in QoL. On this basis, it is unlikely
that decision-makers in the NHS will support the routine use of the fistula plug.
DOI: 10.3310/hta23210 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 21
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Jayne et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xv

Scientific summary
Background
Fistula-in-ano is a common proctological condition that affects mostly younger people and is a source of
chronic morbidity. The aim of fistula surgery is to eradicate the disease while preserving anal sphincter
function. The efficacy of the Surgisis® anal fistula plug (Cook Medical, Bloomington, IN, USA) in the
treatment of trans-sphincteric fistula-in-ano has been variably reported. A 2007 National Institute for Health
and Care Excellence review of the evidence on the fistula plug concluded that ‘evidence of the efficacy and
cost-effectiveness of the [fistula plug] is not adequate for it to be used without special arrangements for
consent and for audit or research’ (National Institute for Health and Care Excellence. Closure of Anorectal
Fistula Using a Suturable Bioprosthetic Plug. Interventional Procedures Guidance [IPG221]. London: National
Institute for Health and Care Excellence; 2007. Reproduced with permission). The Fistula-In-Ano Trial (FIAT)
was commissioned by the National Institute for Health Research Health Technology Assessment programme
in 2009 to undertake a rigorous valuation of the safety, efficacy and cost-effectiveness of the fistula plug in
comparison with existing surgical techniques to treat trans-sphincteric fistula-in-ano.
Objectives
To undertake a randomised comparison of the safety, efficacy and cost-effectiveness of the Surgisis anal
fistula plug with surgeon’s preference for treatment of trans-sphincteric anal fistulas. Surgeon’s preference
included the use of one of several established surgical techniques used to treat trans-sphincteric fistula-in-ano:
fistulotomy, cutting seton, advancement flap and ligation of intersphincteric fistula tract (LIFT). The research
questions included:
i. What is the efficacy of the fistula plug in terms of disease-specific and generic quality of life (QoL)
at 12-month follow-up in comparison with surgeon’s preference?
ii. What are the clinical and radiological healing rates associated with the fistula plug, compared with
surgeon’s preference, at 12-month follow-up?
iii. What are the incontinence rates associated with the fistula plug, compared with surgeon’s preference,
at baseline and at 6- and 12-month follow-up?
iv. What are the complication rates associated with the fistula plug, compared with surgeon’s preference,
at 6-week, 6-month and 12-month follow-up?
v. What are the reintervention rates associated with the fistula plug, compared with surgeon’s preference,
at 6- and 12-month follow-up?
vi. What is the cost-effectiveness of the fistula plug, compared with surgeon’s preference, in the treatment
of trans-sphincteric fistula-in-ano?
Methods
A multicentre randomised controlled trial was undertaken across 53 NHS hospital trusts comparing the
Surgisis anal fistula plug and the surgeon’s preference of advancement flap, cutting seton, fistulotomy
and the LIFT procedure in patients with a confirmed high trans-sphincteric fistula at risk of incontinence
with fistulotomy (high trans-sphincteric was defined as involving approximately one-third or more of the
external sphincter complex). Patients aged ≥ 18 years with a clinical diagnosis of high trans-sphincteric
cryptoglandular fistula-in-ano were eligible if they had previously undergone examination under anaesthesia
(EUA) to characterise the fistula, the fistula tract was ≥ 2 cm in length, only a single internal fistula opening
was present at EUA, they had been treated with a draining seton for a minimum period of 6 weeks prior to
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randomisation and provided informed consent. Patients with low trans-sphincteric, non-cryptoglandular
(e.g. Crohn’s disease, obstetric, irradiation, malignant) or other perineal fistulas (e.g. rectovaginal fistulas,
pouch-vaginal fistulas) were excluded. Patients were also excluded if they had complex disease with more
than one internal fistula opening, if there was clinical evidence of active perianal sepsis or if they had
recurrent anal fistulas previously treated with a fistula plug. Patients with a contraindication to general
anaesthesia, an absolute contraindication to magnetic resonance imaging (MRI) scan or a cultural or
religious objection to the use of pig tissue were excluded.
Participants were randomised in a 1 : 1 ratio to either the Surgisis anal fistula plug group or the surgeon’s
preference group in accordance with a minimisation algorithm to ensure balance of age (< 30, 30–39,
40–49, 50–59, 60–69, ≥ 70 years), American Society of Anesthesiologists (ASA) grade (P1, P2, P3, P4),
planned type of surgery (advancement flap, cutting seton, LIFT procedure, fistulotomy) and presence of
extensions (yes, no).
The primary outcome measure was QoL measured using the validated, symptom-specific Faecal Incontinence
Quality of Life (FIQoL) questionnaire. QoL was assessed at baseline and at 6 weeks, 6 months and 12 months
post randomisation. Secondary outcomes were fistula healing rate at 12 months; faecal incontinence rates
(St Mark’s incontinence score) at baseline, 6 and 12 months; complication rates at 6 weeks, 6 months and
12 months; and reintervention rates at 6 and 12 months. A trial-based cost–utility analysis was undertaken.
Participants were followed up at the time of discharge following surgery and then at 6 weeks, 6 months
and 12 months post randomisation. The trial ended when the last participant had completed 12-month
follow-up. At all follow-up visits, information was collected on complications, reinterventions, serious
adverse events and use of health services. At the 6-week and 6- and 12-month follow-up time points, the
St Mark’s incontinence score was measured and patients completed the FIQoL questionnaire to assess
the impact of faecal incontinence on lifestyle, coping/behaviour, depression/self-perception and level of
embarrassment. All patients underwent MRI at the 12-month time point or at the time of clinical relapse.
Analyses used the intention-to-treat principle, analysing participants in the treatment group to which they
had been assigned at randomisation.
Results
Between May 2011 and March 2016, 304 participants were recruited to the FIAT. The majority had fistulas
classified as ASA I and were aged between 30 and 60 years, and there was a slight predominance of males
(55%). One hundred and fifty-two participants were randomised to the fistula plug group and 152 to
the surgeon’s preference group. The two groups were balanced in terms of baseline age, sex, smoking
status, comorbidities, fistula characteristic and FIQoL score. St Mark’s incontinence scores and EuroQol-5
Dimensions, three-level version, utility scores were marginally higher at baseline in the surgeon’s
preference group. No differences were seen in FIQoL between the fistula plug and surgeon’s preference
groups at 6-week, 6-month or 12-month follow-up. Clinical evidence of fistula healing was reported in 66
of 122 (54%) participants in the fistula plug group and in 66 of 119 (55%) participants in the surgeon’s
preference group at 12 months. MRI showed fistula healing in 54 out of 110 (49%) participants in the
fistula plug group and in 63 out of 112 (56%) participants in the surgeon’s preference group. The clinical
healing rate at 12 months varied depending on the type of surgical procedure performed, being 55%,
64%, 75%, 53% and 42% for fistula plug, cutting seton, fistulotomy, advancement flap and LIFT
procedure, respectively. Faecal incontinence rates were low at baseline, with marginal improvement in
both groups post treatment. Complications were frequent, with 49 out of 142 (35%) participants in
the fistula plug group and 25 out of 137 (18%) participants in the surgeon’s preference group having
experienced complications by the 6-week follow-up, and 28 out of 124 (23%) participants in the fistula
group and 24 out of 121 (20%) participants in the surgeon’s preference group having experienced
complications by the 12-month follow-up. The only significant difference between the groups was in the
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complication rate at 6 weeks (p = 0.002), influenced by a higher rate of unexpected pain in the fistula plug
group. Treatment-specific complications included fistula plug extrusion (16%), cutting seton extrusion (18%),
fistulotomy wound complications (15%), LIFT-related wound complications (15%) and advancement flap
complications (18%). Reinterventions were similarly frequent, having been required in 30 out of 142 (21%)
participants in the fistula plug group and 16 out of 137 (12%) participants in the surgeon’s preference
group by the 6-week follow-up, and in 28 out of 124 (23%) participants in the fistula plug group and
27 out of 121 (22%) participants in the surgeon’s preference group by the 12-month follow-up. There was
no difference between the two groups in time to reintervention. The majority of reinterventions involve
surgical intervention, rather than medical care. The mean total costs were £2738 [standard deviation (SD)
£1151] in the fistula plug group and £2308 (SD £1228) in the surgeon’s preference group (mean difference
£430; p = 0.0174). The average total quality-adjusted life-years (QALYs) gained was marginally higher in the
fistula plug group (0.829, SD 0.174) than in the surgeon’s preference group (0.790, SD 0.212), but this
difference was not statistically significant (p = 0.182). Using multiple imputation and probabilistic sensitivity
analysis, and adjusting for differences in baseline EQ-5D-3L utility, the fistula plug was 35–45% more likely
than surgeon’s preference to be cost-effective at a range of thresholds of willingness to pay for one QALY
of £20,000–30,000.
Conclusions
The Surgisis anal fistula plug was associated with similar FIQoL to surgeon’s preference at the 12-month
follow-up. The clinical healing rates associated with the fistula plug and surgeon’s preference groups were
54% and 55%, respectively, at the 12-month follow-up. The higher costs and highly uncertain QALY gains
associated with the fistula plug mean that this technology is unlikely to be considered a cost-effective treatment
in the UK NHS. The overall poor healing rates associated with the surgical treatment of trans-sphincteric
fistula-in-ano demand that further research be undertaken to better understand the pathophysiology
underlying this common disease. Further analysis of the FIAT data should help to identify clinical and
radiological predictors of fistula response to treatment.
Trial registration
This trial is registered as ISRCTN78352529.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
F istula-in-ano is a common condition, affecting an estimated 1–2 people in 10,000 of the population.1,2It can arise spontaneously, when it is referred to as idiopathic or cryptoglandular, or as a result of an
underlying pathology, such as inflammatory bowel disease, malignancy, trauma or irradiation. Idiopathic
fistula-in-ano is the commonest aetiology. Anal fistula most commonly affects people in the third to fifth
decades of life. It results in significant morbidity through chronic sepsis, causing pain and discharge,
and financial implications through time off work and repeated hospital admissions. For those patients
who suffer anal sphincter dysfunction as a result of fistula surgery, there is the added distress of faecal
incontinence.
The majority of fistulas are low, incorporating only the lower portion of the anal sphincter complex and, as
such, are amenable to simple fistulotomy (surgical laying open of the fistula tract), with a reasonable expectation
of cure and little risk of incontinence. The remaining ‘high fistulas’, as determined by incorporation of more
than one-third of the anal sphincter complex, present a management problem. To cure these fistulas, the tract
connecting the internal and external fistula openings has to be eradicated with minimal sacrifice of the sphincter
muscle in order to preserve continence.
A variety of surgical treatments have been described for high anal fistulas, but none offers the panacea of
fistula eradication with guaranteed preservation of continence. Fistulotomy, cutting seton and advancement
flap have all been advocated for high fistulas with varying degrees of success. Fistulotomy is associated
with low recurrence rates, variously reported to be between 2% and 9%,3,4 but may be associated with a
change in continence in up to 50% of patients.5 The use of a cutting seton appears to reduce the rate of
incontinence, but does not completely eliminate it, with recurrence rates reported to be between 0% and 8%.
Minor incontinence is reported in 34–63% of patients treated with a cutting seton, with major incontinence
rates between 2% and 26%.6–12 In addition, the use of a cutting seton is often a protracted process, requiring
repeated examination under anaesthesia (EUA) and frequently a completion fistulotomy. Rectal and anal
advancement flaps have been advocated as a means of closing high fistulas with preservation of the external
sphincter muscle. However, fistula recurrence rates of 25–54% have been reported, with a change of
continence in 30–35% of patients.13,14 Ligation of the intersphincteric fistula tract (LIFT) has recently been
described for trans-sphincteric and complex fistulas.15 Data are currently limited to single-centre studies and
only one small randomised controlled trial (RCT). A systematic review and meta-analysis in 2014 reported
successful fistula healing in 73% of patients with minimal morbidity and postoperative incontinence.16
Anal fistula plugs offer an alternative approach to the treatment of anal fistulas. They are composed of
bioprosthetic or synthetic materials and used to occlude the fistula tract and provide a physical scaffold for
ingrowth of host regenerative cells to promote healing. Several fistula plugs have been developed, but
the BioDesign Surgisis® anal fistula plug (Cook Medical, Bloomington, IN, USA), composed of acellular,
lyophilised porcine intestinal submucosa, is the most established. Initial encouraging results from Johnson
et al.,17 reporting closure rates of up to 87%, were not reproduced in later studies. A systematic review
and meta-analysis published in 2010, including 12 studies and 317 patients, reported a variable healing
rate in complex fistula, ranging from 35% to 87%, but with minimal morbidity or incontinence.18 The
main factor determining failure appeared to be early plug extrusion, which was observed in 4–41% of
cases. A subsequent meta-analysis in 2016, comparing the fistula plug with advancement flap, reported
similar healing rates, but with less incontinence associated with the plug.19 Although the use of the plug
conferred a greater procedure cost, this was offset by a shorter recovery period.
In 2008, the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme
issued a call for research proposals to investigate the clinical effectiveness and cost-effectiveness of
biosynthetic plugs in the treatment of high anal fistula. This was in response to the increasing adoption of the
fistula plug into clinical practice against a background of uncertain clinical efficacy and potential increased
costs associated with the new technology. An adequately powered RCT was needed to fill the evidence gap,
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with the primary outcome focusing on patient-reported quality of life (QoL) and secondary outcomes
including fistula healing rates, complications, incontinence rates and cost-effectiveness.
The Fistula-In-Ano Trial (FIAT) was designed to address these criteria. The Surgisis anal fistula plug was
chosen as the intervention, given its predominance in the market at that time. Owing to the number of
alternative surgical techniques, a pragmatic comparator group was chosen, ‘surgeon’s preference’, to
encompass the range of surgical practice. This initially included fistulotomy, cutting seton and advancement
flap; subsequently, in 2011, the LIFT procedure was added as it gained clinical popularity.
This report presents the final results from the NIHR HTA FIAT. It is the largest known RCT assessing the
fistula plug and the largest known trial evaluating different surgical techniques for fistula-in-ano.
INTRODUCTION
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Chapter 2 Methods
T rial-related information including the protocol, patient information sheets, consent forms and the casereport forms (CRFs) are available at www.birmingham.ac.uk/fiat (accessed 1 February 2018). Please also
see the protocol on the project page.20 A list of protocol variations is given in Table 1.
TABLE 1 Summary of protocol changes
Revision
number
From protocol
version number;
date
To protocol version
number; date Summary of changes
1 1.0; 15 April 2010 1.1; 18 January 2011 l Members of the DMEC and TSC added to the protocol
l Protocol contained the appendices, which included the
CRFs, introduction of a new CRF (post-operative form)
and minor changes for clarification made to the other
CRFs (e.g. rewording of the questions to remove any
ambiguity and to provide clarification)
2 1.1; 18 January 2011 2.0; 20 May 2011 l The LIFT procedure added as a fourth option in the
surgeon’s preference arm of the trial
l Details of radiology review added to the protocol
l Details of stratification variables added to the protocol
l Details of type of withdrawal added to the protocol
l Minor changes and updates made to the CRFs contained
in the appendices of the protocol
3 2.0; 20 May 2011 3.0; 8 February 2012 l Change of the version of the Surgisis anal fistula plug
used within the trial
¢ The new version of the Surgisis anal fistula plug is a
modified form of the previous versions, incorporating a
‘button head’ in an attempt to improve fixation at the
internal opening and thus reduce the possibility of
plug extrusion
l Price of plug updated
l Clarification provided to state that MRI scans for all FIAT
patients will be collected
l Recommendation for the timing of randomisation made
l Protocol updated with details on the technique for plug
insertion amended to reflect the use of the new version
of the Surgisis anal fistula plug that incorporates a
button head
l Clarification on the time point at which the baseline QoL
form should be completed
l Appendices updated
¢ Updated version of the randomisation
notepad inserted
4 3.0; 8 February 2012 3.1; 7 April 2014 l TMG members updated
l Protocol updated to provide clarification on when
randomisation should be performed
l Minor changes made to the appendices of the protocol
(namely ‘confidential once completed’ added to the
header/footer of the CRFs)
5 3.1; 7 April 2014 4.0; 22 February
2016
l Protocol updated to reflect the reduction in sample size
and extension to the recruitment period of the trial
l The recruitment period was extended by 12 months and
the recruitment target lowered to 300 patients
DMEC, Data Monitoring and Ethics Committee; MRI, magnetic resonance imaging; TMG, Trial Management Group;
TSC, Trial Steering Committee.
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Objectives
The aim of the FIAT was to compare the Surgisis anal fistula plug with standard surgical treatments for high
trans-sphincteric anal fistulas. Standard surgical treatments were the surgeon’s preference of advancement
flap, cutting seton, fistulotomy and LIFT procedure.
The specific trial objectives were:
l to determine whether or not the use of the Surgisis anal fistula plug, compared with standard surgical
techniques, results in an improvement in symptom-specific QoL
l to determine whether or not the use of the Surgisis anal fistula plug, compared with standard surgical
techniques, results in a difference in:
¢ fistula healing rates
¢ complication and reintervention rates
¢ faecal incontinence rates
¢ cost-effectiveness
¢ health economic benefits.
Trial design
The FIAT is a pragmatic, Phase III, multicentre RCT with a health economic evaluation. Patients with a
confirmed high trans-sphincteric fistula at risk of incontinence with fistulotomy (involving approximately
one-third or more of the external sphincter complex) were randomised between the insertion of the
Surgisis anal fistula plug and the surgeon’s preference of advancement flap, cutting seton, fistulotomy
and LIFT procedure (Figure 1).
Fistula plug
insertion
Surgeon’s
preference
EUA: trans-sphincteric fistula more
than one-third of sphincter complex
Insertion of draining seton
Randomise
MRI fistulography
Advancement
flap Cutting seton Fistulotomy LIFT
FIGURE 1 Trial schema. MRI, magnetic resonance imaging.
METHODS
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Participants
Inclusion criteria
l Clinical diagnosis of high trans-sphincteric cryptoglandular fistula-in-ano.
l Patients must have undergone a prior EUA to characterise the nature of the fistula.
l The fistula tract should be ≥ 2 cm in length.
l Only a single internal fistula opening should be present at EUA, such that the fistula is suitable for
treatment by insertion of a single fistula plug.
l Patients must have been treated with a draining seton for a minimum period of 6 weeks prior
to randomisation.
l Patients must be aged ≥ 18 years and able to provide informed consent.
l Fistulas must be of cryptoglandular aetiology.
Exclusion criteria
l Unable/unwilling to provide informed consent.
l Contraindication to general anaesthesia.
l Low trans-sphincteric fistulas.
l Non-cryptoglandular fistulas (e.g. Crohn’s disease, obstetric, irradiation, malignant, etc.).
l Other perineal fistulas (e.g. rectovaginal fistulas, pouch-vaginal fistulas, etc.).
l Complex disease in which more than one internal fistula opening is present and requiring concurrent
insertion of more than one fistula plug.
l Clinical evidence of active perianal sepsis. In the event that there is disagreement between clinical and
radiological assessment of active sepsis/collection, the clinical opinion will prevail.
l Cultural or religious objection to the use of pig tissue.
l Absolute contraindication to magnetic resonance imaging (MRI) (e.g. cardiac pacemaker).
l Patients with recurrent anal fistulas previously treated with a fistula plug.
As it is not known how the presence of an extension or secondary track (defined as an area of sepsis
branching away from the primary fistula track, which may include a horseshoe extension or blind sinus
track) affects the healing rates of the fistula plug, for the purposes of the FIAT these findings on EUA or
MRI were not considered exclusion criteria. However, no evidence of undrained sepsis, either clinically or
radiologically, prior to randomisation into the trial was permitted.
Rationale for choice of inclusion and exclusion criteria
The FIAT recruited patients with cryptogenic trans-sphincteric anal fistulas at risk of incontinence with
fistulotomy (involving approximately one-third or more of the external sphincter complex).
Patients with recurrent fistulas previously treated by any means other than a fistula plug were eligible for
participation in the trial. Patients were not eligible if insertion of a second fistula plug for the treatment of
recurrent fistulation was planned.
For the purposes of this trial, a high fistula was defined as one that, on clinical grounds, runs a significant
risk of incontinence if treated with fistulotomy (i.e. potentially involves a significant portion of the external
sphincter complex). A low fistula is defined as one that can be treated with fistulotomy with minimal risk
of long-term incontinence (i.e. has minimal involvement of the external sphincter complex).
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Magnetic resonance imaging fistulography prior to randomisation
All patients must have had MRI within 6 months prior to randomisation.
The purpose of the initial MRI was:
l to provide assessment for evidence of ongoing active perianal sepsis or undrained collection after
seton insertion
l to provide baseline imaging for comparison with the scan either at 12 months for the assessment of
healing or sooner if there is treatment failure (recurrence)
l to confirm the findings at EUA (i.e. consistent with a trans-sphincteric fistula of cryptoglandular origin
involving approximately one-third or more of the external sphincter muscle).
AllMRIwasperformedinaminimumoftwoplanes,whichincludedaxialandcoronalorientationswiththe
imagingplaneinclinedtotheanalcanal,usingeitheraSTIR(shorttauinversionrecovery)orfat-saturatedT2
sequencewithamaximumslicethicknessof5mm.Thinnerslicesoradditionalsequencesandimaging
planeswerepermittedaccordingtolocalradiologistpreference,typeofmagneticresonancescannerand
patientfactors.
Ifundrainedcollections/extensionswere identifiedonthe initialMRIscan,MRIwasrepeated(usingthe
sameparametersdescribedabove)aftersurgical interventiontoensureresolutionpriortorandomisation.
StandardisationofMRItechniqueamongrecruitingsiteswasassuredbyholdingdedicatedtraining
sessions ledbythenamedFIATradiologist (Tolan).CentralreviewofallMRIstudies(pre-randomisation
and12-monthfollow-up)wasperformed.
Recruitmentandrandomisation
Trialsites
Fifty-threeUKhospitaltrustsopenedtorecruitmenttotheFIAT(seeAppendix1forrecruitingcentres).
Standardisationoffistulaplug insertionwasensuredthroughmandatoryattendanceataFIATsurgical
workshop.Allparticipatingsurgeonswerealsorequiredtohaveperformedaminimumofthreefistula
plug insertions.
AllparticipatingradiologistswererequiredtoattendaFIATradiologyworkshoptoqualityassure
interpretationoftheMRIscansusedtoconfirmtrialeligibility.
Patientscreening
Aspartofroutine investigation,patientsunderwentEUAtocharacterisethefistula,accordingtoParks
etal.’s21 classification,todrainanyaccompanyingsepsisandto insertadrainingseton.Thesetonwas left
insituforaminimumof6weeks,duringwhichtimeMRIwasperformedtofurthercharacterisethefistula.
Informedconsent
Potentialparticipantswere identifiedfromthreesettings:
1. from the outpatient clinic, in the case of patients presenting with de novo or recurrent perianal
sepsis/fistula in whom a high anal fistula was suspected or established
2. from the outpatient clinic, in the case of patients referred specifically for treatment of complex anal fistulas
3. following acute admission for treatment of perianal sepsis.
METHODS
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The informed consent process was supported by the use of patient information sheets. Potential participants
received a full explanation of the aim, trial treatment, anticipated benefits and potential hazards of taking
part in the trial. It was stressed that the patient was free to refuse to take part or withdraw from the trial
at any time. Owing to the length of the screening process for inclusion in the FIAT, all patients had an
appropriate length of time to consider inclusion, to read the patient information sheet and to discuss
participation with others outside the site research team. Adequate opportunity was given to ask questions.
Written consent was obtained from the participants using the latest version of the informed consent form.
Copies of the form were filed in the hospital notes and investigator site file and sent to the Birmingham
Clinical Trials Unit (BCTU); the original was given to the patient.
Randomisation
Randomisation was performed once the EUA, seton insertion and MRI assessment had been completed
and informed consent obtained. It was recommended that patients were randomised on admission for
surgery or as close to the date of surgery as was possible.
Trial participants were randomised online via a secure 24-hour internet-based randomisation service or by a
telephone call to the BCTU.
Participants were randomised in a 1 : 1 ratio to either the surgeon’s preference or the fistula plug.
The randomisation used a minimisation algorithm to avoid chance imbalances in important stratification
variables. The stratification variables were age (< 30, 30–39, 40–49, 50–59, 60–69, ≥ 70 years), American
Society of Anesthesiologists (ASA) grade (P1, P2, P3, P4), planned type of surgery (advancement flap,
cutting seton, LIFT procedure, fistulotomy) and presence of extensions (yes, no).
Interventions
Participants were randomised to receive either the fistula plug or the surgeon’s preference (advancement
flap, fistulotomy, cutting seton or LIFT procedure).
The technique for the placement of the fistula plug was standardised in accordance with the manufacturer’s
recommendations for best practice, with all participating surgeons attending a mandatory training session
followed by preceptorship with the first cases.
Anal fistula plug
It was recommended that patients receive a preoperative phosphate enema as bowel preparation and a
single dose of intravenous prophylactic antibiotics at the induction of anaesthesia. The choice of antibiotic
prophylaxis was at the surgeon’s discretion.
The draining seton was cut and a silk suture secured to one end and the seton removed, which pulled the
silk suture into the fistula tract. The silk suture was tied to the end of a Cook fistula brush (Cook Medical,
Bloomington, IN, USA), which was used to gently debride the fistula tract. The surgeon could choose to
irrigate the fistula tract with saline solution or hydrogen peroxide.
Based on the appearance of the fistula tract, the surgeon decided whether a 7 mm or a 4 mm button
fistula plug was required. The selected Surgisis anal fistula plug was rehydrated for 2 minutes in saline
solution and secured to the silk suture.
The plug was pulled into the internal opening until resistance was met. The button head of the plug was
secured to the internal opening and internal sphincter with a 2/0 Vicryl (Ethicon Inc., Somerville, NJ, USA) or
equivalent absorbable suture. At the surgeon’s discretion, a mucosal flap was raised to cover the button head.
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The tip of the plug was cut flush with the external opening and if necessary the external opening was
enlarged to facilitate drainage.
Postoperatively, patients were permitted to eat and drink as tolerated. No further antibiotics were
administered and analgesics were administered as necessary. On discharge patients were advised to
avoid all strenuous exertion for a period of 2 weeks.
Control arm: surgeon’s preference
The standard surgical techniques used to treat high trans-sphincteric fistula were grouped together as a
single comparator and termed ‘surgeon’s preference’. All four techniques were standardised for the trial.
Advancement flap
Patients received a preoperative phosphate enema as bowel preparation and a single dose of intravenous
prophylactic antibiotics at the induction of anaesthesia. The choice of antibiotic prophylaxis was at the
surgeon’s discretion.
The location of the internal opening was identified and the draining seton removed. A vascularised flap
of rectal tissue (rectal flap) or anoderm (anal flap) was mobilised off the underlying internal sphincter or
subcutaneous fat and the site of the internal opening on the flap was excised. It was permissible to close
the fistula tract with an absorbable suture as it passed through the internal sphincter. The mobilised flap
was advanced over the site of the internal opening and sutured to the underlying internal sphincter with
an absorbable suture. Postoperatively, patients were permitted to eat and drink as tolerated. No further
antibiotics were administered. Stool softeners, bulking agents and analgesics were administered as
necessary.
Fistulotomy
Patients received a preoperative phosphate enema as bowel preparation. No perioperative antibiotics were
administered unless there was a specific indication (e.g. prosthetic heart valve). The location of the internal
opening was identified and the draining seton removed. The course of the primary tract, and of any
secondary tracts, was delineated with a fistula probe and the tract(s) laid open. The fistulotomy wound
was permitted to be marsupialised as required. Postoperatively, patients were permitted to eat and drink as
tolerated. No further antibiotics were be administered. Stool softeners, bulking agents and analgesics were
administered as necessary.
Cutting seton
Patients received a preoperative phosphate enema as bowel preparation. No perioperative antibiotics were
administered unless there was a specific indication (e.g. prosthetic heart valve). The location of the internal
opening was identified and the draining seton removed. The course of the fistula tract was delineated with
a fistula probe and a 1/0 Prolene (Ethicon Inc., Somerville, NJ, USA) or equivalent non-absorbable seton
material passed through the external opening, primary tract and internal opening. If necessary, the skin
bridge between the external opening and the external sphincter was divided. The seton was tied firmly
around the fistula tract and the contained sphincter muscle. Postoperatively, patients were permitted
to eat and drink as tolerated. Analgesics were administered as necessary. No further antibiotics were
administered.
Ligation of intersphincteric fistula tract procedure
Patients received a preoperative phosphate enema as bowel preparation and a single dose of intravenous
prophylactic antibiotics at the induction of anaesthesia. The choice of antibiotic prophylaxis was at the
surgeon’s discretion. The draining seton was removed and, if helpful, the fistula tract marked by a probe.
An intersphincteric dissection was performed to identify and isolate the fistula tract. The tract was ligated
and divided. A suture may be placed to secure fistula closure at the surgeon’s discretion. The external
fistula tract was curetted and left open to allow drainage. The intersphincteric wound was permitted to be
left open or closed.
METHODS
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Blinding
Given the interventions and the outcomes, it was not possible to blind the surgeons, the participants or
the outcome assessors.
Trial procedures and assessments
Following recruitment into the trial, participants underwent a clinical examination and measurement of
St Mark’s incontinence scores. The baseline Faecal Incontinence Quality of Life (FIQoL) and the EQ-5D were
completed.
Data on fistula classification according to Parks et al.21 and on the use of antibiotics and bowel preparation
at the induction of anaesthesia, along with technical details of the surgical procedures, were collected
intraoperatively. The surgeon’s opinion of the usefulness of the baseline MRI scan as a guide to surgery
was also recorded.
Information on the use of postoperative analgesia, immediate complications and reinterventions was
collected at the time of discharge.
Participants were followed up at 6 weeks, 6 months and 12 months post randomisation. The trial ended
once all participants had completed 12-month follow-up.
At each follow-up visit, a physical examination was performed to determine evidence of fistula healing.
Data on bleeding, unexplained pain and septic events, as well as any other complication thought to be
related to the intervention, were collected. Medicinal and surgical reintervention rates (i.e. intervention
required for an ongoing complication) and St Mark’s incontinence scores were collected at each follow-up
visit. Additionally, the FIQoL and EQ-5D questionnaires were completed at the same time points.
At 12 months, all patients underwent follow-up MRI.
Data on serious adverse events (SAEs) were collected at all time points.
Serious adverse events
Any adverse events meeting the definition of a SAE were recorded on a standardised SAE form and faxed
to the BCTU within 24 hours of the local principal investigator (PI) or a member of their research team
becoming aware of the event. The PI was responsible for assigning causality to the SAE before reporting.
For the purposes of the FIAT, SAEs included, but were not limited to:
l unexpected events occurring during the surgical intervention (e.g. excessive bleeding)
l significant postoperative bleeding above that normally expected following the surgical intervention, and
any bleeding requiring transfusion or surgical intervention for haemostasis
l urinary retention requiring catheterisation
l postoperative pain above that normally expected following the surgical intervention
l perianal or perineal sepsis requiring hospitalisation or surgical intervention
l faecal incontinence or defecatory disturbance above that normally expected following the surgical
intervention
l complications related to the administration of the general anaesthetic or other medications (e.g. allergic
response to antibiotics)
l unexpected events related to MRI fistulography.
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Outcome measures
The primary outcome measure for the trial was QoL measured using the validated, symptom-specific FIQoL.
QoL was assessed at baseline, at 6 weeks and at 6 and 12 months post randomisation.
Symptom-specific QoL was chosen as the primary outcome, rather than fistula healing rates, as it reflects
the primary aim of fistula surgery (to produce symptom relief while maintaining anal sphincter function
and preserving symptom-specific QoL).
The secondary outcome measures were:
l fistula healing rate at 12 months
l faecal incontinence rates (as measured by St Mark’s incontinence score) at baseline and at 6 and
12 months
l complication rates at 6 weeks and at 6 and 12 months
l rates of reintervention at 6 and 12 months
l generic QoL assessed EQ-5D and visual analogue scale scores at baseline, 6 weeks, 6 months and
12 months.
Fistula healing at 12 months was assessed by clinical examination. To be deemed to have healed, there
had to be no visible external opening and no sign of ongoing sepsis or discharge.
Sample size
The primary outcome measure in the FIAT is symptom-specific QoL measured using the FIQoL questionnaire
at baseline, 6 weeks, 6 months and 12 months.
It was estimated that a total of 400 patients would need to be recruited in a 1 : 1 ratio (200 patients to the
fistula plug group and 200 patients to the surgeon’s preference group) to be able to detect a small to
moderate treatment effect [effect size 0.3 standard deviation (SD)] (i.e. a difference in the primary end
point between the two arms of the trial). To allow for a 20% non-compliance rate (non-acceptance, loss
to follow-up, incomplete data), the aim was to recruit a total of 500 patients.
The choice of the 0.3 SD treatment effect size was pragmatic. An effect size of 0.2 SD is considered small,
0.5 moderate and 1.0 large.23 Randomisation of 500 patients in total would provide good statistical power
(80% at p < 0.05) to detect an effect size of 0.25 SD, high power (78% at p < 0.01) to detect an effect
size of 0.3 SD and very high power (97% at p < 0.01) to detect an effect size of 0.4 SD.
Recruitment to the FIAT was slower than anticipated for a variety of reasons. Lack of surgical equipoise and
availability of the plug outside the trial contributed to the low recruitment rate, but the main reason was a
lower prevalence of eligible patients than expected. The most common reasons for ineligibility were complex
fistula and reclassification owing to MRI results; all patients underwent MRI and a higher proportion than
anticipated were reclassified. This led to a change in the diagnostic threshold. The assumptions in the original
application were based on routine practice and traditional clinical classification at the time; most surgeons
were not using MRI. Practice changed during, and potentially as a result of, the trial, and the unintended
consequence was that MRI became more commonplace.
In January 2015, it was agreed with the HTA programme that the sample size for the FIAT would be
reduced. If 300 patients were randomised (270 plus 10% dropout), then the FIAT would have 69% power
to detect a small to moderate (0.3 SD) treatment effect, or 98% power to detect a moderate (0.5 SD)
treatment effect (with α = 0.05).
METHODS
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Statistical methods
The primary outcome measure in the FIAT is symptom-specific QoL measured using the FIQoL questionnaire at
baseline and at 6 weeks, 6 months and 12 months. The questionnaire comprises 29 multiple-choice questions
grouped into four domains: lifestyle, coping/behaviour, depression/self-perception and embarrassment. Data
obtained from the questionnaire were converted into scores using the validated method provided by the
developers. Longitudinal plots of mean scores at baseline and over time by treatment group were produced
for visual presentation of the data. The primary analysis is a comparison of the mean difference in FIQoL
scores between the treatment groups from a repeated measures model (a statistically efficient approach
that allows all of the follow-up data collated during the trial to be used, which further enhances statistical
power). The model incorporates the 6-week, 6-month and 12-month time points. In addition, the baseline
score is included as a covariate in the model. Separate models were constructed for each of the four
domains of the FIQoL questionnaire. Further models that included a time-by-treatment interaction term
were also fitted. Mean differences and 95% confidence intervals (CIs) were reported.
In addition to the primary adjusted intention-to-treat (ITT) analysis, a ‘per-protocol’ analysis was undertaken
for the primary outcome as a sensitivity analysis to explore the potential effect of non-adherence to the
randomised allocation. Participants were classified with respect to the first intervention they received, rather
than the intervention to which they were randomised. Participants who did not have surgery were excluded
from the analysis.
Four a priori subgroup analyses were planned for the primary outcome. These subgroups were for the
minimisation variables: age at randomisation (< 30, 30–39, 40–49, 50–59, 60–69, ≥ 70 years), ASA grade
(P1, P2, P3, P4), planned type of surgery (advancement flap, cutting seton, LIFT procedure, fistulotomy)
and presence of extensions (yes, no). A treatment group-by-subgroup interaction parameter was included
in the repeated measures model to assess whether or not there were any differences in the treatment
effect across the different strata. Mean differences and 95% CIs were reported.
Data regarding fistula healing were recorded at the 6-week, 6-month and 12-month time points. The
fistula healing rates in the two treatment groups were compared using a chi-squared test. Relative risks
and 95% CIs were reported.
Faecal incontinence was measured using the St Mark’s incontinence score at baseline and at 6 weeks,
6 months and 12 months. St Mark’s incontinence scores were modelled at each time point, including
treatment as a covariate. Mean differences and 95% CIs were reported.
Complication data relating to bleeding, unexplained pain and septic events were recorded at discharge
(following operative procedure) and at 6 weeks, 6 months and 12 months. Complication data relating
to urinary retention were recorded at discharge (following operative procedure) only. Data regarding
participants’ need for reintervention were also recorded at the same time points. Reinterventions were
classified as medicinal or surgical by the chief investigator of the trial. The overall complication rates and
reintervention rates in the two treatment groups were compared at each time point separately using a
chi-squared test. Relative risks and 95% CIs were reported. The proportions of participants experiencing
each individual type of complication were also presented, as were the proportions of participants receiving
medicinal or surgical reintervention. Time to first reintervention and time to first surgical reintervention
were both analysed using a Cox regression model. Hazard ratios and 95% CIs were reported in both cases.
General QoL was assessed using the EuroQol-5 Dimensions, three-level version (EQ-5D-3L), questionnaire
at baseline and at 6 weeks, 6 months and 12 months. The questionnaire comprises five multiple-choice
questions, each with three possible responses, and a visual analogue scale from 0 to 100. Data obtained
from the questionnaire were converted into scores using the validated method provided by the developers.
Longitudinal plots of mean scores at baseline and over time by treatment group were produced for visual
presentation of the data. The scores in the two treatment groups were compared using repeated-measures
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models in the same manner as described for the primary outcome. Separate models were constructed for
the health status score and visual analogue scale.
Subgroup analyses were carried out for fistula healing, faecal incontinence and EQ-5D-3L in the same
manner as described for the analysis of subgroups for the primary outcome.
The SAE data were summarised descriptively. The SAE data were also analysed as a dichotomous variable,
with each participant classed as either having or not having experienced a SAE. The two treatment groups
were compared using a chi-squared test.
Estimates of treatment effects are presented with 95% CIs and p-values are two-tailed with a p-value < 0.05
considered to be statistically significant. No corrections for multiple tests were made. All analyses were carried
out using SAS® software version 9.4 (SAS Institute Inc., Cary, NC, USA) or Stata® 14 (StataCorp LP, College
Station, TX, USA).
Cost-effectiveness analysis
The aim of the economic evaluation was to assess the cost-effectiveness of the Surgisis anal fistula plug
compared with surgeon’s preference for the treatment of trans-sphincteric fistula-in-ano.
The evaluation was performed using a UK NHS and Personal Social Services (PSS) perspective. The evaluation
estimated the incremental cost-effectiveness ratios (ICERs) of the fistula plug compared with the surgeon’s
preference at 12 months. It was planned that the results would be extrapolated using a decision-analytic
model to estimate lifetime cost-effectiveness.
Resource use data
Resource use data collected from patients at 6 weeks, 6 months and 12 months were combined with data
collected during the trial, including operation costs. Unit costs to estimate the total health resource use
cost for each participant were informed by national sources, such as the Personal Social Services Research
Unit (PSSRU) Unit Costs of Health and Social Care 2017,24 NHS Reference Costs25 and the British National
Formulary (BNF) 2018.26
Utilities and quality-adjusted life-years
Health-related quality of life (HRQoL) of the trial participants was estimated using the EQ-5D-3L, which was
administered alongside the participant resource use questionnaires. EQ-5D-3L scores were obtained at
baseline and at 6 weeks, 6 months and 12 months, with differences between treatment arms assessed
using two sample t-tests.
The primary health-related outcome measure used in the cost-effectiveness analysis was the quality-adjusted
life-year (QALY), measured using the QoL scores obtained from the EQ-5D-3L questionnaires [in line with the
National Institute for Health and Care Excellence’s (NICE) reference case27]. The responses to the EQ-5D-3L
questionnaire were converted to utilities using standard UK tariff values.28 QALYs were calculated by
multiplying these values by the time spent in each state, with QoL linearly interpolated for the periods
between the four observations provided in the trial data. Average QALYs between adjacent time points were
calculated to generate smoothed estimates between the time points.
Missing data
First, patient-level analysis on complete cases was conducted; this required data on total QALYs and total
costs. The total cost per participant was calculated from the UK NHS and PSS perspectives by adding the
costs associated with the operations, including the costs of inpatient stay and postoperative costs, as well
as the costs of further consultations, prescriptions, treatment and applicable intervention costs for all
participants for whom response data were available. Multiple imputation by chained equations was then
METHODS
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used to impute missing EQ-5D-3L data and individual components of total costs at all three time points.
No imputation was undertaken for baseline values.
Economic model
It was anticipated that the cost-effectiveness of the Surgisis anal fistula plug beyond the trial period would
be assessed through Markov modelling, allowing the outcomes to be extrapolated beyond the trial period.
The Markov model would be formed using the 12-month data from the trial in addition to the published
literature on longer-term outcomes and expert judgement, as necessary.
Sensitivity analysis
Probabilistic sensitivity analysis was used to assess uncertainty and the results presented using a
cost-effectiveness plane and cost-effectiveness acceptability curve.
Patient and public involvement
The FIAT was developed by the Research and Audit Committee of the Association of Coloproctology of
Great Britain and Ireland (ACPGBI) and supported by the ACPGBI membership and Executive Council
(which includes a patient liaison group). Two independent patient representatives were involved in the trial
from conception as members of the Trial Management Group.
Ethics approval, regulations and trial registration
Ethics approval for the trial was granted by the National Research Ethics Service Committee East Midlands –
Derby Research Ethics Committee (reference number 10/H0405/29).
The trial was conducted in accordance with the recommendations guiding physicians in biomedical
research involving human subjects, adopted by the 18th World Medical Association General Assembly in
Helsinki, Finland, June 1964,29 and its subsequent amendments, the Research Governance Framework for
Health and Social Care,30 and the applicable UK statutory instruments including the Data Protection Act
199831 and the International Conference on Harmonisation Guidelines for Good Clinical Practice.
The trial was prospectively registered as ISRCTN78352529.
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Chapter 3 Results
Screening
A total of 1355 patients were assessed for eligibility. Of these, 731 patients did not meet the eligibility
criteria, 100 patients were eligible but were not randomised and 220 patients were still undergoing
screening at the time of trial closure.
Reasons for ineligibility were available for 581 (79%) out of the 731 ineligible patients (Figure 2). Of these
581 patients, 437 (75%) presented with ineligible fistula morphology: complex fistula disease (n = 92),
extrasphincteric fistulas (n = 3), fistula healed (n = 23), fistula tract too short (n = 18), high supralevator fistula
(n = 1), intrasphincteric fistula (n = 43), low fistula (n = 122), non-cryptoglandular fistula (n = 71), other perineal
fistula (n = 32), other unspecified fistula reason (n = 2), no evidence of fistula (n = 19), superficial fistula (n = 9)
and suprasphincteric fistula (n = 2).
A total of 94 (16%) patients did not meet the eligibility requirements because of the presence of
coexistent anorectal pathology (e.g. anal fissure, haemorrhoids, pilonidal sinus).
A total of 33 (6%) patients were ineligible because of their treatment pathway: previously treated with the
fistula plug (n = 18), draining seton not required (n = 5), draining seton not yet in place for 6 weeks (n = 1),
cutting seton already in place (n = 1), draining seton to remain in situ (n = 1), contraindication to MRI
(n = 5) and MRI outside acceptable time frame (n = 2).
Thirteen (2%) patients were not suitable for surgery; one patient was excluded because she was pregnant
and three patients were unable to give informed consent.
Of the 100 patients who were eligible but not randomised, 79 did not want to participate in the trial and
the remainder indicated a preference for one of the treatment allocations (12 wanted to receive a fistula
plug and nine wanted to receive the surgeon’s preferred treatment).
n = 437 (75%)
n = 94 (16%)
n = 33 (6%) 
n = 13 (2%)
Fistula morphology
Other anorectal pathology
Treatment pathway
Unsuitable for surgery
Reason
FIGURE 2 Reasons for ineligibility.
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Recruitment
The FIAT opened to recruitment in May 2011, and the first participant was recruited into the trial on
24 May 2011. A total of 304 participants were recruited and randomised, with the last patient entering
the trial on 10 March 2016. Participants were split equally between the two randomised treatment
allocations: 152 participants were randomised to receive the fistula plug and 152 were randomised to
the surgeon’s preference. The 304 participants were recruited from 40 centres, 75% of those open to
recruitment. The number of participants recruited at each site ranged from 1 to 32 (see Appendix 2).
Recruitment figures by month are shown in Figure 3 and recruitment figures by centre are shown in
Table 2. All participants had reached the 12-month follow-up time point by March 2017.
Participant flow
Of the 304 participants randomised into the FIAT, a total of eight (2.6%) withdrew their consent to remain
in the trial. These withdrawals occurred at a range of time points through the trial: five participants withdrew
consent prior to any trial treatment, one participant withdrew consent post surgery, one participant withdrew
consent before the 6-month time point and one participant withdrew consent before the 12-month time
point. Three patients were lost to follow-up: two participants prior to the 6-month time point and one
participant before the 12-month time point. In the case of participants who withdrew consent or were lost
to follow-up, the data collected up to the point of trial exit were used in the analyses. See Figure 4 for the
Consolidated Standards of Reporting Trials (CONSORT) flow diagram with further details of participant flow.
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FIGURE 3 Recruitment by month.
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TABLE 2 Recruitment by centre
Centre
Number of participants
randomised
Southend University Hospital NHS Foundation Trust (Southend Hospital) 32
Leeds Teaching Hospitals NHS Trust (St James’s University Hospital/Leeds General Infirmary) 28
Portsmouth Hospitals NHS Trust (Queen Alexandra Hospital) 20
Nottingham University Hospitals NHS Trust (Queen’s Medical Centre) 20
Central Manchester University Hospitals NHS Foundation Trust (Manchester Royal Infirmary) 17
Sandwell and West Birmingham Hospitals NHS Trust (Sandwell General Hospital) 16
Cardiff & Vale University Health Board (Llandough University Hospital/University Hospital of Wales) 13
Taunton & Somerset NHS Foundation Trust (Musgrove Park Hospital) 11
Burton Hospitals NHS Foundation Trust (Queen’s Hospital Burton) 10
University Hospitals Bristol NHS Foundation Trust (Bristol Royal Infirmary) 9
Dorset County Hospital NHS Foundation Trust (Dorset County Hospital) 9
Royal United Hospitals Bath NHS Foundation Trust (Royal United Hospitals Bath) 8
NHS Highland (Raigmore Hospital) 8
Chesterfield Royal Hospital NHS Foundation Trust (Chesterfield Royal Hospital) 8
Oxford University Hospitals NHS Foundation Trust (Churchill Hospital/John Radcliffe Hospital) 8
Wirral University Teaching Hospital NHS Foundation Trust (Arrowe Park Hospital) 7
University Hospitals Birmingham NHS Foundation Trust (Queen Elizabeth Hospital Birmingham) 7
Norfolk and Norwich University Hospitals NHS Foundation Trust (Norfolk and Norwich
University Hospital)
6
Homerton University Hospital NHS Foundation Trust (Homerton University Hospital) 6
University Hospitals of Leicester NHS Trust (Leicester General Hospital) 6
Croydon Health Services NHS Trust (Croydon University Hospital) 5
Mid Essex Hospital Services NHS Trust (Broomfield Hospital) 5
The Mid Yorkshire Hospitals NHS Trust (Pinderfields General Hospital/Dewsbury and District
Hospital)
5
Gloucestershire Hospitals NHS Foundation Trust (Cheltenham General Hospital) 4
Imperial College Healthcare NHS Trust (Charing Cross Hospital/St Mary’s Hospital) 4
Heart of England NHS Foundation Trust (Birmingham Heartlands Hospital/Good Hope Hospital) 4
Ashford and St Peter’s Hospitals NHS Foundation Trust (St Peter’s Hospital) 3
Calderdale and Huddersfield NHS Foundation Trust (Huddersfield Royal Infirmary) 3
Southport and Ormskirk Hospital NHS Trust (Southport and Formby District General Hospital) 3
George Eliot Hospital NHS Trust (George Eliot Hospital) 3
Yeovil District Hospital NHS Trust (Yeovil District Hospital) 2
Hillingdon Hospitals NHS Foundation Trust (Hillingdon Hospital) 2
Ipswich Hospital NHS Trust (Ipswich Hospital) 2
Royal Liverpool and Broadgreen University Hospitals NHS Trust (The Royal Liverpool University
Hospital)
2
South Tees Hospitals NHS Foundation Trust (The James Cook University Hospital) 2
Barking, Havering and Redbridge University Hospitals NHS Trust (Queen’s Hospital) 2
continued
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TABLE 2 Recruitment by centre (continued )
Centre
Number of participants
randomised
St Helens and Knowsley Teaching Hospitals NHS Trust (Whiston Hospital) 1
Poole Hospital NHS Foundation Trust (Poole Hospital) 1
The Royal Wolverhampton NHS Trust (New Cross Hospital) 1
Aneurin Bevan University Health Board (Nevill Hall Hospital) 1
Assessed for eligibility
(n = 1355)
Randomised
(n = 304)
Surgisis anal fistula plug
(n = 152)
Received Surgisis anal fistula plug
(n = 135)
Did not receive Surgisis anal fistula plug
(n = 15)
Number of participants still in trial
(n = 150)
• Withdrew, n = 0
• Died, n = 1
• LFU, n = 0
Surgery
• Withdrew, n = 1
• Died, n = 0
• LFU, n = 1
• Withdrew, n = 0
• Died, n = 0
• LFU, n = 1
• Withdrew, n = 1
• Died, n = 0
• LFU, n = 0
• Withdrew, n = 0
• Died, n = 0
• LFU, n = 1
• Withdrew, n = 1
• Died, n = 0
• LFU, n = 0
Surgeon’s preference
(n = 152)
• Received cutting seton, n = 5
• Received fistulotomy, n = 6
• Received LIFT, n = 1
• No surgery performed, n = 3
Number of participants still in trial
(n = 149)
6 weeks
Number of participants still in trial
(n = 147)
6 months
Number of participants still in trial
(n = 146)
12 months
Received allocated intervention
(n = 143)
Did not receive allocated intervention
(n = 6)
Number of participants still in trial
(n = 149)
Surgery
Reasons for exclusion
• Ineligible, n = 731
• Eligible but not
   randomised, n = 100
• Underwent screening when
   trial closed to recruitment,
   n = 220
• Received Surgisis anal plug, n = 3
• Received Surgisis anal plug (privately), n = 1
• No surgery performed, n = 2
Number of participants still in trial
(n = 148)
6 weeks
Number of participants still in trial
(n = 147)
6 months
Number of participants still in trial
(n = 146)
12 months
FIGURE 4 Consolidated Standards of Reporting Trials flow diagram. LFU, lost to follow-up.
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Data completeness
Compliance with data collection was good (see Appendix 3). Baseline data were complete for 151 (99%)
of the 152 participants in the fistula plug group and for 150 (99%) of the 152 participants in the surgeon’s
preference group. Baseline radiology, which was mandatory for inclusion in the trial, was carried out in all
participants. Follow-up MRI data were available for analysis for a total of 110 (75%) of the 146 of participants
in the fistula group and 112 (77%) of the 146 participants in the surgeon’s preference group. Compliance
with the collection of postoperative follow-up data was excellent, with complete data available for 99% of
the trial population at the operative and postoperative time points. There was a gradual loss of surgical
follow-up data with time, but levels remained acceptable (94% at 6 weeks, 88% at 6 months and 85% at
12 months). Similarly, the completeness of data collected from the patient-reported questionnaires (EQ-5D-3L
and FIQoL) decreased with the increased length of follow-up (being 87% at 12 months).
Baseline data
The baseline characteristics of recruited participants, overall and by randomisation group, are shown in
Table 3. The majority of participants in each group were classified as ASA I (normal, healthy patient) and were
aged between 30 and 60 years (mean 45.1 years, range 18–83 years). There were more men (n = 167, 55%)
than women (n = 137, 45%). The most frequently selected surgical procedures, prior to randomisation,
were the LIFT procedure (n = 116, 38%) and cutting seton (n = 114, 38%), followed by advancement flap
(n = 66, 22%) and fistulotomy (n = 8, 2%). There was no difference in comorbidity between the groups,
with smokers making up 23% and 25% of the fistula plug and surgeon’s preference groups, respectively.
TABLE 3 Baseline characteristics of recruited participants
Patient characteristic
Surgisis anal fistula plug
(N= 152)
Surgeon’s preference
(N= 152)
All participants
(N= 304)
Minimisation variable
ASA grade, n (%)
P1 (normal, healthy patient) 118 (78) 117 (77) 235 (77)
P2 (mild systemic disease) 31 (20) 30 (20) 61 (20)
P3 (severe systemic disease) 3 (2) 5 (3) 8 (3)
Age at randomisation (years), n (%)
< 30 23 (15) 22 (15) 45 (15)
30–39 39 (26) 36 (24) 75 (25)
40–49 35 (23) 45 (30) 80 (26)
50–59 33 (22) 29 (19) 62 (21)
60–69 12 (8) 10 (6) 22 (7)
≥ 70 10 (6) 10 (6) 20 (6)
Type of surgery, n (%)
Advancement flap 32 (21) 34 (22) 66 (22)
Fistulotomy 6 (3) 2 (1) 8 (2)
Cutting seton 57 (38) 57 (38) 114 (38)
LIFT procedure 57 (38) 59 (39) 116 (38)
Secondary extensions at baseline EUA,
n/N (%)a
19/107 (18) 17/105 (16) 36/212 (17)
continued
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TABLE 3 Baseline characteristics of recruited participants (continued )
Patient characteristic
Surgisis anal fistula plug
(N= 152)
Surgeon’s preference
(N= 152)
All participants
(N= 304)
Patient characteristic
Age (years)
Age at randomisation, mean (SD, n) 45.2 (14.1, 152) 44.9 (13.7, 152) 45.1 (13.9, 304)
Range 20–83 18–80 18–83
Sex, n (%)
Male 86 (57) 81 (53) 167 (55)
Female 66 (43) 71 (47) 137 (45)
Missing 1 2 3
Smoker, n (%) 35 (23) 38 (25) 73 (24)
Missing 1 2 3
St Mark’s incontinence scoreb
Median (IQR, n) 4 (1–6, 151) 4 (2–8, 152) 4 (2–7, 303)
Range 0–21 0–18 0–21
Incontinence for solid stools, n (%)
Never 132 (89) 134 (89) 266 (89)
Rarely 6 (4) 6 (4) 12 (4)
Sometimes 8 (5) 8 (5) 16 (5)
Weekly 0 1 (1) 1 (1)
Daily 3 (2) 1 (1) 4 (1)
Missing 3 2 5
Incontinence for liquid stools, n (%)
Never 112 (75) 103 (69) 215 (72)
Rarely 10 (7) 18 (12) 28 (9)
Sometimes 21 (14) 19 (13) 40 (14)
Weekly 4 (3) 5 (3) 9 (3)
Daily 2 (1) 5 (3) 7 (2)
Missing 3 2 5
Incontinence for gas, n (%)
Never 100 (67) 91 (61) 191 (64)
Rarely 12 (8) 10 (7) 22 (7)
Sometimes 24 (16) 29 (19) 53 (18)
Weekly 3 (2) 3 (2) 6 (2)
Daily 10 (7) 17 (11) 27 (9)
Missing 3 2 5
Alteration in lifestyle, n (%)
Never 74 (50) 72 (48) 146 (49)
Rarely 13 (9) 10 (7) 23 (8)
Sometimes 20 (13) 22 (15) 42 (14)
Weekly 7 (5) 14 (9) 21 (7)
Daily 35 (23) 32 (21) 67 (22)
Missing 3 2 5
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TABLE 3 Baseline characteristics of recruited participants (continued )
Patient characteristic
Surgisis anal fistula plug
(N= 152)
Surgeon’s preference
(N= 152)
All participants
(N= 304)
Wear a pad/plug, n (%) 73 (49) 63 (42) 136 (46)
Missing 4 2 6
Taking constipation medicine, n (%) 9 (6) 19 (13) 28 (9)
Missing 4 2 6
Lack of ability to defer defecation for
15 minutes, n (%)
25 (17) 34 (23) 59 (20)
Missing 4 2 6
Fistula history
Acute sepsis/abscess, n (%) 63 (42) 71 (48) 134 (45)
Missing 2 4 6
Chronic sepsis/fistula, n (%) 98 (65) 84 (56) 182 (60)
Missing 1 2 3
First/recurrent fistula, n (%)
First 101 (70) 98 (70) 199 (70)
Recurrent 44 (30) 42 (30) 86 (30)
Missing/unknownc 7 12 19
Previous fistula surgery, n (%) 64 (42) 73 (48) 137 (45)
Number of previous fistula surgeries
Median (IQR, n) 2 (1–2, 63) 1 (1–3, 73) 2 (1–2, 136)
Range 1–13 1–12 1–13
Type of previous fistula surgery, n/N (%)
Fistulotomy 10/63 (16) 13/73 (18) 23/136 (17)
Seton 57/63 (90) 64/73 (88) 121/136 (89)
Advancement flap 2/63 (3) 2/73 (3) 4/136 (3)
Fistula plug 0/63 (0) 0/73 (0) 0/136 (0)
Other 11/63 (17) 23/73 (32) 34/136 (25)
Missing 1 0 1
Previous anorectal surgery, n (%) 29 (19) 31 (21) 60 (20)
Missing 1 3 4
EUA
Trans-sphincteric, n (%) 150 (99) 149 (99) 299 (99)
Missing 1 2 3
Length of primary tract (cm)
Median (IQR, n) 3.5 (3.0–4.0, 148) 3.0 (2.5–4.0, 145) 3.0 (3.0–4.0, 293)
Range 1.5–12.0 1.5–8.0 1.5–12.0
Level of internal opening in relation to dentate line, n (%)
Below 12 (8) 21 (14) 33 (11)
At 96 (64) 99 (66) 195 (65)
Above 43 (28) 30 (20) 73 (24)
Missing 1 2 3
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TABLE 3 Baseline characteristics of recruited participants (continued )
Patient characteristic
Surgisis anal fistula plug
(N= 152)
Surgeon’s preference
(N= 152)
All participants
(N= 304)
Extent of external sphincter involvement, n (%)
Less than one-third 18 (12) 20 (13) 38 (12)
One-third 5 (3) 3 (2) 8 (3)
More than one-third 127 (85) 127 (85) 254 (85)
Missing 2 2 4
Secondary tracts, n (%) 17 (11) 19 (13) 36 (12)
Missing 1 2 3
Number of secondary tracts
Median (IQR, n) 1.0 (1.0–1.0, 17) 1.0 (1.0–1.0, 19) 1.0 (1.0–1.0, 36)
Range 1.0–1.0 1.0–1.0 1.0–1.0
Supralevator extension, n (%) 4 (3) 4 (3) 8 (3)
Missing 1 2 3
Horseshoe extensions, n (%) 10 (7) 6 (4) 16 (5)
Missing 4 3 7
Active sepsis/abscess, n (%) 27 (18) 26 (17) 53 (18)
Missing 1 2 3
Seton inserted, n (%) 149 (99) 149 (99) 298 (99)
Missing 1 2 3
Radiology MRI
Seton present in track, n (%)
No 30 (20) 28 (18) 58 (19)
Yes 90 (59) 103 (68) 193 (64)
Cannot identify 32 (21) 21 (14) 53 (17)
Fistula type, n (%)
Superficial 3 (2) 1 (1) 4 (1)
Intersphincteric 14 (9) 12 (8) 26 (9)
Trans-sphincteric 132 (87) 138 (90) 270 (89)
Supralevator 0 (0) 1 (1) 1 (< 1)
Extrasphincteric 1 (1) 0 (0) 1 (< 1)
Blind sinus 1 (1) 0 (0) 1 (< 1)
Missing 1 0 1
Extensions present, n (%) 41 (27) 35 (23) 76 (25)
Number of extensions
Median (IQR, n) 1.0 (1.0–1.0, 41) 1.0 (1.0–1.0, 35) 1.0 (1.0–1.0, 76)
Range 1.0–2.0 1.0–3.0 1.0–3.0
Location of extensions, n/N (%)
Intersphincteric 17/41 (41) 19/35 (54) 36/76 (47)
Ischioanal fossa 24/41 (60) 18/35 (51) 42/76 (56)
Supralevator 6/41 (15) 2/35 (6) 8/76 (11)
RESULTS
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The overall incidence of baseline incontinence symptoms, as judged by the St Mark’s incontinence score,
was low and similar in the two groups [fistula plug, median incidence 4 (interquartile range 1–6); surgeon’s
preference, median incidence 4 (interquartile range 2–8)]. A total of 136 (46%) of the 304 participants
reported wearing a pad, which might reflect fistula discharge rather than true anal incontinence.
Chronic sepsis was reported in 98 (65%) patients in the fistula plug group and in 84 patients (56%) in
the surgeon’s preference group, with the remainder reporting acute or acute on chronic sepsis. Recurrent
fistulas were experienced by 30% of patients in each group, with 64 (42%) patients in the fistula plug
group and 73 (48%) patients in the surgeon’s preference group undergoing previous fistula surgery.
Overall, the number of prior fistula surgeries was similar between the groups (median 2, range 1–13),
with the most frequent operations being seton drainage in 121 of 136 (89%) patients and fistulotomy in
23 of 136 (17%) patients.
All fistulas were deemed to be trans-sphincteric at EUA, although data were missing for one participant in
the fistula plug group and two participants in the surgeon’s preference group. The morphology of the
fistulas at baseline EUA was similar in both groups, with an overall median primary tract length of 3.0 cm
(range 1.5–12.0 cm) and secondary tracts present in 36 (12%) patients. All patients underwent insertion of
a draining seton, with the exception of one participant in the fistula plug group and two participants in the
surgeon’s preference group for whom data were missing.
In around one-third of participants, gadolinium and oedema MRI sequences were obtained, with similar
practices observed at baseline and on follow-up assessment. Baseline MRI characterised the fistula
morphology as trans-sphincteric in 132 out of 152 (87%) participants in the fistula plug group and in
138 out of 152 (91%) participants in the surgeon’s preference group, with low numbers of intersphincteric
(overall 26, 9%) and superficial (overall 4, 1%) fistulas reported. Secondary extensions on MRI were
reported in 25% of cases and at EUA in 12% of cases, with similar numbers of secondary extensions
reported in the two groups (overall median 1, range 1–3).
The majority of surgeons (overall 255/304, 84%) only reviewed the MRI report prior to surgery, with only
around half actually reviewing the images. Approximately half of surgeons felt that MRI was a useful guide
to surgery, with the other half reporting little or no benefit. Review of the MRI findings was reported to
alter the surgical approach to a major degree in 12 (4%) of 304 cases and to a minor degree in 37 (12%)
of 304 cases.
TABLE 3 Baseline characteristics of recruited participants (continued )
Patient characteristic
Surgisis anal fistula plug
(N= 152)
Surgeon’s preference
(N= 152)
All participants
(N= 304)
MRI concordant with EUA, n (%) 50 (33) 4 (3) 102 (34)
Missing 0 2 2
MRI depicts additional findings vs. EUA,
n (%)
11 (7) 10 (7) 21 (7)
Missing 0 2 2
IQR, interquartile range.
a Secondary extensions at baseline EUA were not added to the minimisation procedure until 10 July 2012, version 2.2 of
the randomisation notepad.
b St Mark’s incontinence scores range from 0 to 24, where lower scores indicate less incontinence. When a total score was
not computable from the individual St Mark’s domains, the score provided at randomisation was used. The one
participant for whom St Mark’s score was missing had a colostomy.
c First/recurrent fistula was deemed unknown when both first and recurrent were answered ‘yes’, or both were
answered ‘no’.
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Compliance with randomisation allocation
Of the 152 participants randomised to the fistula plug group, 135 received their randomised allocation.
In 15 participants (9.9%), treatment was non-compliant with the allocated treatment (five received a cutting
seton, six received fistulotomy, one received LIFT and three did not receive any surgery). Two participants
withdrew from the trial prior to surgery and their treatment is not known.
Of the 152 participants randomised to the surgeon’s preference group, 143 received some form of surgical
intervention. Six participants (3.9%) were known to have been non-compliant with their randomised treatment
allocation (four received a fistula plug and two did not receive any surgery). Three participants withdrew
from the trial prior to surgery and their treatment is not known. At randomisation, all investigators had to
indicate which of the four surgeon’s preference options (advancement flap, fistulotomy, LIFT or cutting
seton) would be performed if the participant were to be randomised to the surgeon’s preference group.
In total, 85% of participants received the type of surgery that was planned (Table 4). Only two fistulotomies
were planned, but 13 were carried out.
Overall compliance with randomised treatment was 91.4% (278/304).
Primary end point: quality of life
The primary objective of the FIAT was to compare the fistula plug with standard treatments for high
trans-sphincteric anal fistulas in terms of QoL. Symptom-specific QoL was chosen rather than fistula healing
rates because it reflects the primary aim of fistula surgery: to provide symptom relief while maintaining
anal sphincter function and preserving symptom-specific QoL.
The validated questionnaire used in the FIAT to assess symptom-specific QoL was the FIQoL. Data from this
questionnaire were collected at baseline and at 6 weeks, 6 months and 12 months. The questionnaire
comprises 29 multiple-choice questions grouped into four domains: lifestyle, coping/behaviour, depression/
self-perception and embarrassment. FIQoL domain scores range from 1 to 4, where higher scores indicate
higher QoL.
The primary analysis of the FIAT is a comparison of the mean difference in FIQoL scores between Surgisis
anal fistula plug and surgeon’s preference from a repeated-measures model incorporating the 6-week,
6-month and 12-month time points, where the baseline score is included as a covariate in the model
(Table 5). Separate models have been constructed for each of the four domains of the FIQoL questionnaire.
Further models were also fitted, which included a time-by-treatment interaction term to identify any
change in treatment over time.
TABLE 4 Planned surgery vs. received surgery for the 143 patients randomised to the surgeon’s preference group
who received surgical intervention
Planned surgery
Received surgery
Advancement flap Cutting seton LIFT procedure Fistulotomy Total
Advancement flap 25 2 3 2 32
Cutting seton 0 43 3 7 53
LIFT procedure 0 2 52 2 56
Fistulotomy 0 0 0 2 2
Total 25 47 58 13 143
RESULTS
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No significant differences were seen in any of the four domains between the fistula plug group and
surgeon’s preference group. Models including the treatment-by-time interaction term were also
non-significant and, thus, there is no evidence of a change in treatment effect over time.
Figures 5–8 provide longitudinal plots of mean FIQoL scores over time by treatment group for each domain
of the FIQoL questionnaire.
In addition to the primary-adjusted ITT analysis, a ‘per-protocol’ analysis was undertaken for the primary
outcome as a sensitivity analysis to explore the potential effect of non-adherence to the randomised
allocation (Table 6 and Appendix 4). Participants were classified with respect to the first intervention they
received rather than the intervention to which they were randomised. In total, 155 participants received
the surgeon’s preference (143 randomised to the surgeon’s preference; 12 randomised to the fistula plug)
and 139 participants received a fistula plug (four randomised to the surgeon’s preference; 135 randomised
to the fistula plug). Ten participants did not have surgery and have not been included in this analysis.
TABLE 5 Primary treatment analysis of the FIQoL questionnaire
FIQoL domain
Surgisis anal fistula
plug, mean (SD, n)
Surgeon’s preference,
mean (SD, n)
Mean differencea
(95% CI) p-value
Treatment by
time, p-value
FIQoL: lifestyle
Baseline 3.46 (0.75, 138) 3.34 (0.83, 131) 0.03 (–0.10 to 0.15) 0.67 0.68
6 weeks 3.49 (0.76, 127) 3.42 (0.82, 126)
6 months 3.57 (0.73, 124) 3.50 (0.77, 128)
12 months 3.60 (0.70, 125) 3.54 (0.75, 128)
FIQoL: coping/behaviour
Baseline 3.30 (0.75, 138) 3.14 (0.88, 131) 0.11 (–0.03 to 0.24) 0.11 0.31
6 weeks 3.39 (0.76, 127) 3.18 (0.89, 126)
6 months 3.44 (0.79, 124) 3.31 (0.90, 128)
12 months 3.43 (0.83, 124) 3.33 (0.85, 128)
FIQoL: depression/self-perception
Baseline 3.04 (0.77, 132) 2.99 (0.81, 120) 0.09 (–0.06 to 0.24) 0.22 0.87
6 weeks 3.13 (0.78, 115) 3.03 (0.85, 118)
6 months 3.23 (0.76, 114) 3.16 (0.91, 117)
12 months 3.29 (0.85, 115) 3.20 (0.85, 118)
FIQoL: embarrassment
Baseline 3.26 (0.82, 132) 3.08 (0.87, 120) 0.12 (–0.05 to 0.29) 0.18 0.06
6 weeks 3.34 (0.84, 115) 3.09 (0.92, 117)
6 months 3.34 (0.85, 114) 3.29 (0.89, 118)
12 months 3.35 (0.89, 116) 3.25 (0.95, 118)
a Positive values favour Surgisis anal fistula plug.
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FIGURE 5 Mean FIQoL score: lifestyle domain.
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FIGURE 6 Mean FIQoL score: coping/behaviour domain.
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FIGURE 7 Mean FIQoL score: depression/self-perception domain.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
0.0
Patients
0 6 26 52
132
120
115
117
114
118
116
118
0.5
1.0
1.5
2.0
FI
Q
o
L 
em
b
ar
ra
ss
m
en
t 
sc
o
re
2.5
3.0
3.5
4.0
Follow-up assessment (weeks)
Fistula plug
Surgeon’s preference
Treatment group
Surgeon’s preference
Fistula plug
FIGURE 8 Mean FIQoL score: embarrassment domain.
TABLE 6 Per-protocol analysis of the FIQoL questionnaire
FIQoL domain
Surgisis anal fistula
plug, mean (SD, n)
Surgeon’s preference,
mean (SD, n)
Mean differencea
(95% CI) p-value
Treatment by
time, p-value
FIQoL: lifestyle
Baseline 3.46 (0.75, 130) 3.35 (0.82, 136) 0.09 (–0.04 to 0.21) 0.17 0.54
6 weeks 3.54 (0.71, 123) 3.40 (0.83, 129)
6 months 3.59 (0.72, 118) 3.48 (0.78, 132)
12 months 3.63 (0.67, 120) 3.52 (0.78, 132)
FIQoL: coping/behaviour
Baseline 3.33 (0.73, 130) 3.14 (0.87, 136) 0.15 (0.01 to 0.28) 0.03 0.12
6 weeks 3.45 (0.72, 123) 3.16 (0.89, 129)
6 months 3.46 (0.78, 118) 3.29 (0.91, 132)
12 months 3.45 (0.82, 120) 3.31 (0.86, 131)
FIQoL: depression/self-perception
Baseline 3.05 (0.78, 124) 2.99 (0.79, 125) 0.13 (–0.02 to 0.28) 0.08 0.46
6 weeks 3.18 (0.75, 111) 3.01 (0.85, 121)
6 months 3.25 (0.76, 109) 3.15 (0.91, 120)
12 months 3.31 (0.82, 110) 3.19 (0.87, 122)
FIQoL: embarrassment
Baseline 3.26 (0.81, 124) 3.09 (0.86, 125) 0.17 (–0.001 to 0.34) 0.051 0.02
6 weeks 3.39 (0.81, 111) 3.08 (0.92, 120)
6 months 3.37 (0.85, 109) 3.27 (0.89, 121)
12 months 3.40 (0.87, 111) 3.22 (0.95, 122)
a Positive values favour Surgisis anal fistula plug.
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Similar to the ITT analysis, the per-protocol analysis failed to show significant differences in any of the
domains of FIQoL across the four time points measured (see Appendix 4). A marginal improvement in
FIQoL was observed in all domains at 6 weeks following surgery and was maintained until the 12-month
follow-up assessment.
Prespecified subgroup analyses of the primary outcome were planned for the four variables for which the
randomisation was minimised:
1. age at randomisation (< 30, 30–39, 40–49, 50–59, 60–69, ≥ 70 years)
2. ASA grade (P1, P2, P3, P4)
3. planned type of surgery (advancement flap, cutting seton, LIFT procedure, fistulotomy)
4. presence of extensions (yes, no).
There was no clear evidence to suggest that the treatment effect differed between the different patient
subgroups for any of the four FIQoL domains (Tables 7–10).
TABLE 7 Subgroup analyses for the FIQoL questionnaire: lifestyle domain
Variable Interaction p-value Mean differencea (95% CI) p-value
Age at randomisation (years)
< 30 0.32 –0.22 (–0.53 to 0.10) 0.17
30–39 –0.02 (–0.28 to 0.24) 0.88
40–49 0.03 (–0.21 to 0.27) 0.81
50–59 0.19 (–0.08 to 0.46) 0.17
60–69 0.34 (–0.10 to 0.77) 0.13
≥ 70 –0.06 (–0.55 to 0.44) 0.82
ASA grade
P1 (normal, healthy patient) 0.58 0.01 (–0.14 to 0.15) 0.94
P2 (mild systemic disease) 0.06 (–0.21 to 0.33) 0.66
P3 (severe systemic disease) 0.45 (–0.41 to 1.32) 0.31
Type of surgery
Advancement flap 0.60 0.07 (–0.21 to 0.36) 0.61
Cutting seton 0.06 (–0.14 to 0.26) 0.57
LIFT procedure 0.01 (–0.19 to 0.21) 0.90
Fistulotomy –0.53 (–1.38 to 0.33) 0.22
Presence of extensions
Yes 0.16 –0.23 (–0.61 to 0.15) 0.24
No 0.07 (–0.11 to 0.25) 0.42
a Positive values favour Surgisis anal fistula plug.
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TABLE 8 Subgroup analyses for the FIQoL questionnaire: coping/behaviour domain
Variable Interaction p-value Mean differencea (95% CI) p-value
Age at randomisation (years)
< 30 0.49 –0.09 (–0.42 to 0.24) 0.59
30–39 –0.02 (–0.30 to 0.25) 0.86
40–49 0.12 (–0.13 to 0.38) 0.34
50–59 0.26 (–0.02 to 0.55) 0.07
60–69 0.17 (–0.29 to 0.63) 0.46
≥ 70 0.36 (–0.16 to 0.88) 0.17
ASA grade
P1 (normal, healthy patient) 0.11 0.04 (–0.11 to 0.19) 0.64
P2 (mild systemic disease) 0.29 (0.01 to 0.57) 0.04
P3 (severe systemic disease) 0.75 (–0.15 to 1.65) 0.10
Type of surgery
Advancement flap 0.44 0.11 (–0.19 to 0.41) 0.48
Cutting seton 0.19 (–0.02 to 0.41) 0.07
LIFT procedure 0.05 (–0.16 to 0.26) 0.63
Fistulotomy –0.50 (–1.40 to 0.40) 0.28
Presence of extensions
Yes 0.53 –0.04 (–0.43 to 0.35) 0.84
No 0.10 (–0.09 to 0.28) 0.29
a Positive values favour Surgisis anal fistula plug.
TABLE 9 Subgroup analyses for the FIQoL questionnaire: depression/self-perception domain
Variable Interaction p-value Mean differencea (95% CI) p-value
Age at randomisation (years)
< 30 0.08 –0.28 (–0.64 to 0.08) 0.12
30–39 –0.08 (–0.40 to 0.23) 0.59
40–49 0.15 (–0.14 to 0.43) 0.32
50–59 0.38 (0.08 to 0.68) 0.01
60–69 0.32 (–0.19 to 0.82) 0.22
≥ 70 0.21 (–0.36 to 0.77) 0.48
ASA grade
P1 (normal, healthy patient) 0.19 0.02 (–0.15 to 0.19) 0.82
P2 (mild systemic disease) 0.28 (–0.03 to 0.59) 0.08
P3 (severe systemic disease) 0.63 (–0.33 to 1.59) 0.20
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TABLE 9 Subgroup analyses for the FIQoL questionnaire: depression/self-perception domain (continued )
Variable Interaction p-value Mean differencea (95% CI) p-value
Type of surgery
Advancement flap 0.12 0.21 (–0.12 to 0.54) 0.21
Cutting seton 0.14 (–0.09 to 0.38) 0.23
LIFT procedure 0.05 (–0.18 to 0.28) 0.68
Fistulotomy –1.45 (–2.81 to –0.09) 0.04
Presence of extensions
Yes 0.92 0.05 (–0.37 to 0.47) 0.81
No 0.07 (–0.13 to 0.28) 0.47
a Positive values favour Surgisis anal fistula plug.
TABLE 10 Subgroup analyses for the FIQoL questionnaire: embarrassment domain
Variable Interaction p-value Mean differencea (95% CI) p-value
Age at randomisation (years)
< 30 0.21 –0.23 (–0.66 to 0.19) 0.28
30–39 –0.02 (–0.38 to 0.35) 0.94
40–49 0.22 (–0.12 to 0.56) 0.21
50–59 0.42 (0.06 to 0.78) 0.02
60–69 0.35 (–0.26 to 0.95) 0.26
≥ 70 –0.11 (–0.78 to 0.56) 0.75
ASA grade
P1 (normal, healthy patient) 0.48 0.09 (–0.11 to 0.29) 0.36
P2 (mild systemic disease) 0.15 (–0.21 to 0.52) 0.41
P3 (severe systemic disease) 0.80 (–0.34 to 1.93) 0.17
Type of surgery
Advancement flap 0.12 0.19 (–0.20 to 0.58) 0.34
Cutting seton 0.24 (–0.04 to 0.51) 0.09
LIFT procedure 0.05 (–0.22 to 0.32) 0.70
Fistulotomy –1.71 (–3.34 to –0.07) 0.04
Presence of extensions
Yes 0.77 0.13 (–0.37 to 0.63) 0.61
No 0.05 (–0.19 to 0.29) 0.70
a Positive values favour Surgisis anal fistula plug.
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Secondary outcomes
Fistula healing (clinical assessment)
Fistula healing was recorded at 6 weeks and at 6 and 12 months (Table 11). At the 6-week time point
approximately one-third of participants had clinical evidence of a healed fistula [42/141 (30%) in the fistula
plug group vs. 45/137 (33%) in the surgeon’s preference group]. The proportion of fistulas that were
reported as healed at 6 months was higher in the surgeon’s preference group, but this difference was not
statistically significant. By 12 months, this trend was not apparent, with just over half of fistulas in both the
fistula plug group (n/N = 66/122) and the surgeon’s preference group (n/N = 66/119) reported as healed.
No significant differences between treatment groups in the proportion of patients whose fistula had
healed were seen at any of the time points.
Subgroup analyses of the effect of the four randomisation minimisation factors on 12-month fistula
healing rates showed no clear evidence that the treatment effect differed between the different patient
subgroups (Table 12).
Fistula healing rates by procedure
The fistula healing rates per received procedure and at the various follow-up time points are shown in
Table 13. Forty-one (30%) of 136 participants in the fistula plug group were assessed as clinically healed
by 6 weeks, with a gradual increase to 51 (41%) of 123 participants at 6 months and to 63 (55%) of
115 participants at 12 months. The best-performing procedure, accepting that the numbers treated were
small, appeared to be fistulotomy, with 11 (65%) of 17 participants healed at 6 weeks and 12 (75%) of
16 participants healed at 12 months. Few participants receiving the cutting seton were healed at 6 weeks
(7/48, 15%), but had a gradual increase in healing by 12 months (27/42, 64%). The LIFT procedure
produced clinical healing in 16 (29%) of 55 participants at 6 weeks and in 17 (31%) of 55 participants at
6 months, increasing to 21 (42%) of 50 participants by 12 months.
TABLE 11 Fistula healing rates
Time
Surgisis anal fistula plug
(N= 152)
Surgeon’s preference
(N= 152) Risk ratio (95% CI) p-value
6 weeks
Fistula healing data
available, n
141 137 0.91 (0.64 to 1.29) 0.58
Fistula healing, n (%) 42 (30) 45 (33)
6 months
Fistula healing data
available, n
127 128 0.81 (0.61 to 1.08) 0.14
Fistula healing, n (%) 50 (39) 62 (48)
12 months
Fistula healing data
available, n
122 119 0.98 (0.78 to 1.23) 0.83
Fistula healing, n (%) 66 (54) 66 (55)
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Fistula healing (radiological assessment)
Magnetic resonance imaging data were available for 110 (72%) of 152 participants in the fistula group
and for 112 (74%) of 152 participants in the surgeon’s preference group. Overall, 192 (86%) of
220 participants underwent routine 12-month follow-up MRI, with 31 (14%) undergoing MRI for clinical
relapse prior to the 12-month time point.
Follow-up MRI performed either for clinical relapse or at a routine 12-month follow-up revealed fistula
healing in 54 (49%) of 110 participants in the fistula plug group, compared with 63 (56%) of 112
participants in the surgeon’s preference group (Table 14).
TABLE 12 Fistula healing rates: outcome by subgroup
Subgroup Interaction p-value Risk ratio (95% CI) p-value
Age at randomisation (years)
< 30 0.91 0.74 (0.42 to 1.29) 0.29
30–39 0.94 (0.60 to 1.48) 0.80
40–49 0.94 (0.62 to 1.41) 0.76
50–59 1.17 (0.67 to 2.04) 0.57
60–69 1.14 (0.42 to 3.08) 0.80
≥ 70 1.13 (0.41 to 3.08) 0.82
ASA grade
P1 (normal, healthy patient) 0.42 0.89 (0.68 to 1.16) 0.38
P2 (mild systemic disease) 1.28 (0.78 to 2.10) 0.33
P3 (severe systemic disease) 1.25 (0.22 to 7.22) 0.80
Type of surgery
Advancement flap Model did not converge
Cutting seton
LIFT procedure
Fistulotomy
Presence of extensions
Yes 0.68 1.17 (0.59 to 2.31) 0.66
No 0.99 (0.74 to 1.34) 0.97
TABLE 13 Fistula healing rates per received procedure at each follow-up time point
Time
Treatment received, n/N (%)
Surgisis anal fistula plug Cutting seton Fistulotomy Advancement flap LIFT procedure
6 weeks 41/136 (30) 7/48 (15) 11/17 (65) 11/21 (52) 16/55 (29)
6 months 51/123 (41) 20/40 (50) 14/17 (82) 10/19 (53) 17/55 (31)
12 months 63/115 (55) 27/42 (64) 12/16 (75) 9/17 (53) 21/50 (42)
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Faecal incontinence
Faecal incontinence was recorded at 6 weeks and at 6 and 12 months using the St Mark’s incontinence
score. The score ranges from 0 to 24, where higher scores indicate a higher level of incontinence. The
mean (SD) scores for each treatment group at each time point are given in Table 15. The baseline
incontinence scores tended to be higher in the surgeon’s preference group than in the fistula plug group,
but with similar SDs. No significant differences in mean incontinence score between treatment groups
were seen at any of the follow-up time points. The numerically higher mean values in the surgeon’s
preference group at all time points are of marginal significance and do not translate into a clinically
meaningful difference.
Subgroup analyses of the St Mark’s incontinence score data showed no clear evidence that the treatment
effect differed between the different patient subgroups (Table 16).
Complications
Data on bleeding, unexplained pain and septic events were recorded at discharge (following the operative
procedure) and at 6 weeks, 6 months and 12 months (Table 17). Data on urinary retention were recorded
at discharge only.
Postoperative complications were few and rates were similar in both groups [fistula plug group, n/N = 4/147
(3%); surgeon’s preference group, n/N = 2/144 (1%)], indicating that fistula surgery carries a low level of
morbidity.
The only significant difference observed between the two groups was at 6 weeks, when more participants
in the fistula plug group than in the surgeon’s preference group had experienced complications (fistula plug
group n/N = 49/142, 35%, vs. surgeon’s preference group n/N = 25/137, 18%; p = 0.002). This difference
appeared to be due to a greater proportion of participants experiencing protracted pain in the fistula plug
group.
TABLE 15 St Mark’s incontinence score
Time
Surgisis anal fistula
plug, mean (SD, n)
Surgeon’s preference,
mean (SD, n)
Mean differencea
(95% CI) p-value
Baseline 4.54 (4.15, 151) 5.24 (4.78, 152)
6 weeks 3.72 (4.22, 134) 3.87 (4.97, 132) –0.15 (–1.26 to 0.96) 0.79
6 months 3.06 (4.44, 120) 3.61 (4.55, 117) –0.55 (–1.70 to 0.60) 0.35
12 months 3.22 (4.54, 120) 3.65 (4.91, 112) –0.44 (–1.66 to 0.79) 0.48
a Values < 0 favour Surgisis anal fistula plug.
TABLE 14 Radiological assessment of fistula healing rates per procedure at the 12-month follow-up
Assessment
Treatment received, n/N (%)
Surgisis anal fistula plug Cutting seton Fistulotomy Advancement flap
LIFT
procedure
12 months: clinical 63/115 (55) 27/42 (64) 12/16 (75) 9/17 (53) 21/50 (42)
12 months: MRI 54/110 (49) 63/112 (57)
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TABLE 16 St Mark’s incontinence score by subgroup
Subgroup Interaction p-value Mean differencea (95% CI) p-value
Age at randomisation (years)
< 30 0.51 1.54 (–1.90 to 4.98) 0.38
30–39 0.82 (–1.67 to 3.30) 0.52
40–49 –1.94 (–4.29 to 0.42) 0.11
50–59 –0.30 (–3.06 to 2.45) 0.83
60–69 –1.50 (–5.68 to 2.68) 0.48
≥ 70 –1.50 (–6.17 to 3.17) 0.53
ASA grade
P1 (normal, healthy patient) 0.75 –0.49 (–1.87 to 0.90) 0.49
P2 (mild systemic disease) –0.08 (–2.68 to 2.52) 0.95
P3 (severe systemic disease) 2.50 (–5.46 to 10.46) 0.54
Type of surgery
Advancement flap 0.40 –1.48 (–4.26 to 1.30) 0.30
Cutting seton –0.20 (–2.17 to 1.77) 0.84
LIFT procedure –0.57 (–2.54 to 1.40) 0.57
Fistulotomy 5.60 (–2.20 to 13.40) 0.16
Presence of extensions
Yes 0.59 –0.09 (–3.81 to 3.63) 0.96
No –1.20 (–2.90 to 0.49) 0.16
a Values < 0 favour Surgisis anal fistula plug.
TABLE 17 General complications
Complication
Surgisis anal fistula
plug (n= 152), n/N (%)
Surgeon’s preference
(n= 152), n/N (%) Risk ratioa (95% CI) p-value
Postoperative
Complications data available 147 144
Complications 4 (3) 2 (1) 1.96 (0.36 to 10.53) 0.42
Bleeding 2/4 (50) 0/2 (0)
Urinary retention 0/4 (0) 1/2 (50)
Unexplained pain 2/4 (50) 1/2 (50)
Septic event 0/4 (0) 0/2 (0)
6 weeks
Complications data available 142 137
Complications 49 (35) 25 (18) 1.89 (1.24 to 2.88) 0.002
Bleeding 9/49 (18) 5/25 (20)
Unexplained pain 32/49 (65) 9/25 (36)
Septic event 15/49 (31) 11/25 (44)
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By 6 and 12 months, the overall complication rates were similar in both groups, with unexpected pain
continuing to be reported at 6 months, particularly in the fistula plug group. Even by 12 months,
unexpected pain was still reported by around one-third of participants in both groups and septic
complications were reported in 50% of the fistula plug group and 38% of the surgeon’s preference
group.
Treatment-specific complications
The treatment-specific complications are reported in Table 18. Plug extrusion was an early complication
reported in 20 (16%) of 126 participants in the fistula plug group, with persistent discharge from the
fistula tract in 47 (45%) of 104 participants at 6 months and 40 (40%) of 101 participants at 12 months.
Wound-related problems were reported in 2 (15%) of 13 participants in the fistulotomy group at 6 weeks,
decreasing to 1 (7%) of 14 participants by 6 months and increasing again to 2 (14%) of 14 participants
at 12 months. Similar rates of wound-related problems were reported following the LIFT procedure.
Complications related to the advancement flap occurred in 4 (18%) of 22 participants at 6 weeks and
persisted in 3 (16%) of 19 participants at 6 months’ follow-up and in 2 (13%) of 16 participants at
12-month follow-up.
TABLE 17 General complications (continued )
Complication
Surgisis anal fistula
plug (n= 152), n/N (%)
Surgeon’s preference
(n= 152), n/N (%) Risk ratioa (95% CI) p-value
6 months
Complications data available 129 129
Complications 27 (21) 27 (21) 1.00 (0.62 to 1.61) 1.00
Bleeding 5/27 (19) 4/27 (15)
Unexplained pain 14/27 (52) 7/27 (26)
Septic event 5/27 (19) 11/27 (41)
12 months
Complications data available 124 121
Complications 28 (23) 24 (20) 1.14 (0.70 to 1.85) 0.60
Bleeding 6/28 (21) 4/24 (17)
Unexplained pain 10/28 (36) 8/24 (33)
Septic event 14/28 (50) 9/24 (38)
a Values < 1 favour Surgisis anal fistula plug.
TABLE 18 Treatment-specific complications
Procedure 6 weeks, n/N (%) 6 months, n/N (%) 12 months, n/N (%)
Fistula plug extrusion 20/126 (16)
Cutting seton extrusion 9/49 (18)
Fistulotomy wound complications 2/13 (15) 1/14 (7) 2/14 (14)
LIFT procedure wound problems 8/53 (15) 6/45 (13) 8/44 (18)
Advancement flap complications 4/22 (18) 3/19 (16) 2/16 (13)
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Reinterventions
Reintervention data were recorded at discharge (following operative procedure) and at 6 weeks, 6 months
and 12 months, and each reintervention was classified as either medical (non-operative intervention) or
surgical (operative intervention) by the clinical members of the Trial Management Team. The overall
analyses of reintervention rates simply consider whether or not the participant received any reintervention
at each time point (it is possible that participants could have received multiple reinterventions). In the
breakdown of reinterventions, each type is counted separately. However, multiple reinterventions of the
same type at the same time point (i.e. medical at 6 weeks) are counted only once. Reintervention data are
shown in Table 19.
Postoperative reinterventions were rare (1% in both groups), highlighting the low immediate morbidity
associated with fistula surgery. A significant difference in reinterventions was observed at the 6-week
follow-up, being higher in the fistula plug group (n/N = 30/142, 21%) than in the surgeon’s preference
group (n/N = 16/137, 12%). This significant difference was lost at 6- and 12-month follow-up, but
reinterventions at 12 months were still common in both groups [fistula plug group, n/N = 28/124 (23%)
vs. surgeon’s preference group, n/N = 27/121 (22%)]. Medical reinterventions were frequent at 6 weeks,
accounting for almost 50% of reinterventions in both arms, but decreased as a proportion of the overall
number of reinterventions with progressive follow-up.
TABLE 19 Reinterventions
Reintervention
Surgisis anal fistula
plug (N= 152)
Surgeon’s preference
(N= 152) Risk ratioa (95% CI) p-value
Postoperative
Complications data available, n 147 144
Reintervention, n (%) 2 (1) 1 (1) 1.96 (0.18 to 21.37) 0.57
Medical, n/N (%) 1/2 (50) 1/1 (100)
Surgical, n/N (%) 1/2 (50) 0/1 (0)
6 weeks
Complications data available, n 142 137
Reintervention, n (%)2 30 (21) 16 (12) 1.81 (1.03 to 3.17) 0.03
Medical, n/N (%) 13/30 (43) 8/16 (50)
Surgical, n/N (%) 18/30 (60) 8/16 (50)
6 months
Complication data available, n 129 129
Reintervention, n (%)2 25 (19) 30 (23) 0.83 (0.52 to 1.34) 0.45
Medical, n/N (%) 3/25 (12) 7/30 (23)
Surgical, n/N (%) 24/25 (96) 24/30 (80)
12 months
Complications data available, n 124 121
Reintervention, n (%)2 28 (23) 27 (22) 1.01 (0.64 to 1.61) 0.96
Medical, n/N (%) 5/28 (18) 2/27 (7)
Surgical, n/N (%) 24/28 (86) 26/27 (96)
a Values < 1 favour Surgisis anal fistula plug.
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Time to first reintervention and time to first surgical reintervention are presented in Figures 9 and 10 ,
respectively. Hazard ratios are computed from a Cox regression model, where values < 1 favour the fistula
plug. No significant differences were seen between the treatment groups.
EuroQol-5 Dimensions, three-level version
The validated questionnaire used in the FIAT to assess general QoL was the EuroQol EQ-5D-3L. Data from
this questionnaire were collected at baseline, and at 6 weeks, 6 months and 12 months. The questionnaire
comprises five domains, each with three possible responses, and a visual analogue scale from 0 to 100.
Responses to the domains are combined to give a HRQoL score, which can range from –0.594 to 1, where
higher scores indicate a higher QoL. Higher values on the visual analogue scale also indicate a higher QoL.
Analyses of the EQ-5D-3L data compare the mean difference in EQ-5D-3L scores between the fistula
plug group and the surgeon’s preference group from a repeated-measures model incorporating the 6-week,
6-month and 12-month time points, where the baseline score will be included as a covariate in the model
(Table 20 ). Separate models have been constructed for both the visual analogue score and the health status
score. Further models that included a time-by-treatment interaction term were also fitted to identify any
change in treatment over time.
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FIGURE 9 Time to first reintervention. Hazard ratio: fistula plug vs. surgeon’s preference 1.05 (95% CI 0.72 to 1.53).
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FIGURE 10 Time to first surgical reintervention. Hazard ratio: fistula plug vs. surgeon’s preference 1.11 (95% CI
0.75 to 1.66).
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There was a marginal improvement in both the HRQoL and the visual analogue score between baseline
and 12-month follow-up in both groups. No significant differences were seen for either the health status
score or the visual analogue score between the fistula plug group and the surgeon’s preference group.
Models including the treatment-by-time interaction term were also non-significant and, thus, there is no
evidence of a change in treatment effect over time.
Subgroup analyses of the health status score and visual analogue score data showed no clear evidence
that the treatment effect differed between the different patient subgroups (Tables 21 and 22).
Serious adverse events
Twenty-four SAEs were reported in 22 participants (7.2%): 14 SAEs in 14 participants (9.2%) in the fistula
plug group and 10 SAEs in eight participants (5.3%) in the surgeon’s preference group (p = 0.19) (Table 23).
All SAEs bar one (death in the fistula plug group) were related to trial treatment.
The most common reason for SAE reporting was a septic event related to the development of a perineal
abscess or fistula recurrence, which accounted for 9 (64%) of 14 cases in the fistula plug group and
8 (80%) of 10 cases in the surgeon’s preference group. There was one accidental death in the fistula plug
group, which was unrelated to the trial.
TABLE 20 EuroQol-5 Dimensions, three-level version, and visual analogue scale scores
Time
Surgisis anal fistula
plug, mean (SD, n)
Surgeon’s preference,
mean (SD, n)
Mean differencea
(95% CI) p-value
Treatment by
time, p-value
Visual analogue scale
Baseline 73.30 (18.67, 139) 74.61 (17.75, 131) 1.66 (–1.45 to 4.77) 0.29 0.41
6 weeks 75.88 (18.44, 128) 75.99 (18.22, 125)
6 months 80.14 (15.63, 124) 77.64 (20.67, 129)
12 months 79.62 (19.04, 125) 79.47 (15.62, 125)
EQ-5D-3L HRQoL
Baseline 0.77 (0.27, 136) 0.76 (0.25, 130) 0.01 (–0.04 to 0.05) 0.76 0.54
6 weeks 0.78 (0.24, 121) 0.77 (0.25, 125)
6 months 0.83 (0.21, 121) 0.79 (0.27, 129)
12 months 0.85 (0.21, 121) 0.82 (0.24, 126)
a Positive values favour Surgisis anal fistula plug.
Note
A higher visual analogue scale and health status score indicates improved QoL.
TABLE 21 EuroQol-5 Dimensions, three-level version HRQoL by subgroup
Subgroup Interaction p-value Mean difference (95% CI) p-value
Age at randomisation (years)
< 30 0.62 –0.05 (–0.16 to 0.06) 0.35
30–39 0.02 (–0.07 to 0.10) 0.72
40–49 –0.002 (–0.08 to 0.08) 0.97
50–59 0.05 (–0.04 to 0.15) 0.26
60–69 –0.06 (–0.20 to 0.09) 0.45
≥ 70 0.07 (–0.10 to 0.25) 0.39
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TABLE 21 EuroQol-5 Dimensions, three-level version HRQoL by subgroup (continued )
Subgroup Interaction p-value Mean difference (95% CI) p-value
ASA grade
P1 (normal, healthy patient) 0.21 0.01 (–0.04 to 0.05) 0.82
P2 (mild systemic disease) –0.02 (–0.11 to 0.07) 0.66
P3 (severe systemic disease) 0.25 (–0.03 to 0.54) 0.09
Type of surgery
Advancement flap 0.46 0.03 (–0.06 to 0.13) 0.51
Cutting seton –0.0001 (–0.07 to 0.07) 1.00
LIFT procedure 0.01 (–0.06 to 0.08) 0.72
Fistulotomy –0.21 (–0.49 to 0.07) 0.14
Presence of extensions
Yes 0.28 –0.06 (–0.18 to 0.06) 0.34
No 0.02 (–0.04 to 0.07) 0.61
TABLE 22 EuroQol-5 Dimensions, three-level version, visual analogue scale scores by subgroup
Subgroup Interaction p-value Mean difference (95% CI) p-value
Age at randomisation (years)
< 30 0.83 2.01 (–6.10 to 10.13) 0.63
30–39 –0.60 (–7.17 to 5.97) 0.86
40–49 2.35 (–3.67 to 8.37) 0.44
50–59 4.19 (–2.73 to 11.11) 0.23
60–69 –3.49 (–14.70 to 7.72) 0.54
≥ 70 5.13 (–7.36 to 17.63) 0.42
ASA grade
P1 (normal, healthy patient) 0.85 1.40 (–2.13 to 4.93) 0.43
P2 (mild systemic disease) 2.09 (–4.52 to 8.70) 0.53
P3 (severe systemic disease) –4.23 (–25.48 to 17.01) 0.70
Type of surgery
Advancement flap 0.29 3.44 (–3.52 to 10.39) 0.33
Cutting seton 3.15 (–1.90 to 8.20) 0.22
LIFT procedure 0.34 (–4.63 to 5.30) 0.89
Fistulotomy –16.72 (–37.84 to 4.41) 0.12
Presence of extensions
Yes 0.84 2.29 (–6.84 to 11.43) 0.62
No 1.23 (–3.00 to 5.46)
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Economic evaluation
The economic evaluation was a within-trial analysis and examined the cost-effectiveness of the fistula plug
compared with standard surgical techniques based on surgeon’s preference from a UK NHS and PSS
perspective.
Unit cost data
Resource use data collected from patients at 6 weeks and at 6 and 12 months were combined with unit
costs to estimate the total health resource use cost for each participant (Table 24).
Unit costs of patient-reported prescriptions
Prescriptions were reported by patients at 6 weeks and at 6 and 12 months, using a free-text field. This led
to many varied entries by participants. Almost all of the prescriptions were for antibiotics, painkillers or
dressings. Given that the price of dressings is negligible, it was assumed that, among participants who
reported receiving one or more prescriptions, 50% received painkillers and 50% received antibiotics, as
reported in Table 25.
Operation-associated costs
The resources used associated with the operations were collected by sites at the time of the operation and
at 6 weeks’ follow-up. The costs are shown in Table 26. Given that no information was collected on the
staff members present during the operations, it was assumed that the following health-care staff were
present at the procedure: anaesthetist, anaesthetic assistant, surgeon, assistant surgeon, scrub nurse and
a circulating nurse.
TABLE 23 Serious adverse events in treatment group
SAE detail Surgisis anal fistula plug (n= 152) Surgeon’s preference (n= 152)
Septic complication 9 8
Unexpected pain 4 0
Urinary retention 0 1
Allergy to seton 0 1
Death 1 0
Total 14 10
TABLE 24 Summary of participant-reported health-care use and associated unit costs
Resource item Cost (£) Source
GP surgery visit 37.00 PSSRU (2017):24 including direct care staff costs with qualification, per participant
contact lasting 9.22 minutes
Nurse at GP surgery 6.45 PSSRU (2017):24 £42 per hour (cost including qualifications), per patient contact
lasting 9.22 minutes
District nurse house visit 77.35 PSSRU (2015):32 nurse specialist (community), £75 per hour with qualification of
patient-related work (not updated in latest publication)
Inflated to 2017 cost year
Walk-in centre 32.94 £28.2333 inflated to 2017 cost year
Hospital A&E department 63.00 Department of Health and Social Care34
A&E, accident and emergency; GP, general practitioner.
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TABLE 25 Summary of participant-reported medication use (prescriptions) and associated unit costs
Drug name and use Price (£) Source
Metronidazole: 400 mg every 8 hours for 7 days 4.10 (21 tablets) BNF (2018)26
Co-codamol: 15 mg/500mg three times a day for 5 days 4.93 (100 tablets) BNF (2018)26
TABLE 26 Operation-related costs
Item Cost (£) Source
Surgisis anal fistula plug 780
Theatre time (per hour) 1144 Information Services Division Scotland35
Elective inpatient excess day 392 NHS Reference Costs, 2017:34 FZ22E Intermediate Anal
Procedures, ≥ 19 years, with CC score 0
Surgeon 107 PSSRU (2017)24 P213: hospital-based doctors –
consultant surgeon
Assistant surgeon 107 PSSRU (2017)24 P213: hospital-based doctors –
consultant surgeon
Anaesthetist 107 PSSRU (2017)24 P213: hospital-based doctors –
consultant surgeon
Assistant anaesthetist 54 PSSRU (2017)24 P209: hospital-based nurses – grade 7
Scrub nurse 54 PSSRU (2017)24 P209: hospital-based nurses – grade 7
Circulating nurse 54 PSSRU (2017)24 P209: hospital-based nurses – grade 7
Perioperative antibiotics: metronidazole
500mg/100 ml infusion (100-ml bags),
one dose = 500mg
62 (20 bags) BNF (2018)26
Postoperative antibiotics: oral
co-amoxiclav (Augmentin,
GlaxoSmithKline, London, UK)
250mg/125 mg every 8 hours
three times per day for 7 days
1.59 (21 tablets) BNF (2018)26
Bowel preparation
Phosphates enema (Formula B)
128 ml, long tube
27.93 BNF (2018)26
Oral preparation: MoviPrep® (Salix
Pharmaceuticals, Bridgewater, NJ, USA)
oral powder, one pair of sachets
10.36 (4 sachets) BNF (2018)26
Analgesics
Morphine sulfate: 10 mg/10 ml solution
for injection ampoules
15 (10 ampoules) BNF (2018)26
Co-codamol: 15 mg/500 mg, two tablets 4.93 (100 tablets) BNF (2018)26
Lactulose [Lacsa (Pty) Ltd, Durban,
South Africa]: 10 g/15 ml oral solution
(15-ml sachet, sugar free)
2.52 (10 sachets) BNF (2018)26
Bulking Fybogel Mebeverine:
effervescent granules in sachets
[Reckitt Benckiser Healthcare (UK) Ltd]
2.72 (30 sachets) BNF (2018)26
Tinzaparin (LEO Pharma, Ballerup,
Denmark) sodium: 3500 units/0.35 ml
solution for injection, pre-filled syringes
27.71 (10 pre-filled
disposable injections)
BNF (2018)26
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Within-trial cost-effectiveness analysis
Cost-effectiveness results: base case
Complete resource use and QALY data were available for 177 participants, with 87 participants in the
fistula plug group and 90 participants in the surgeon’s preference group.
Health-care resource use
The total costs associated with resource use are shown in Table 27. The mean total UK NHS and PSS
resource use costs throughout the whole period of follow-up were £2738 for the fistula plug group and
£2308 for the surgeon’s preference group, with the total mean costs for the fistula plug group being
significantly higher (£430 difference; p = 0.0174). The mean costs attributable to readmissions were higher
for the fistula plug group, but this difference was not significant. Likewise, although the mean costs
attributable to health and social services use outside hospital were higher for the surgeon’s preference
group, this difference was not significant.
Health outcomes
Table 28 shows the (unimputed) EQ-5D-3L scores at baseline, 6 weeks, 6 months and 12 months post
operation. Both treatment groups showed increasing EQ-5D-3L scores from baseline up to 12 months
post operation, with some variation at 6 weeks and 6 months post randomisation in both arms before
increasing again.
On average, the difference between arms was marginal. Independent-sample t-tests indicated that the
changes in the EQ-5D-3L score over time were not statistically significant. The average total QALY gain
over the 12 months was marginally higher in the fistula plug group (0.829) than in the surgeon’s
preference group (0.790), but this difference was not significant (p = 0.182).
Cost-effectiveness results (non-imputed)
Table 29 shows the total costs and EQ-5D-3L-generated QALYs for each of the treatment arms for the
complete-case analysis. Differences in QALYs between groups were not significant, with marginal health
decrements in the surgeon’s preference group compared with the fistula plug group. The mean total cost
was significantly higher for the fistula plug group. The high SD for the deterministic cost estimates reflects
the presence of a few outlying individuals who incurred significant health service costs.
Table 30 provides the probabilistic cost-effectiveness results for the non-imputed data, showing the
incremental costs and benefits as well as the ICER. The results suggest that the fistula plug is associated
with an additional incremental cost of £430 and an incremental QALY gain of 0.039. The ICER shows that
the cost per additional QALY gained is £10,993. Although this would be acceptable based on a willingness
to pay (WTP) of £20,000 per QALY, this value is subject to much uncertainty. The overall net benefit
associated with the fistula plug is positive (£352), suggesting that the fistula plug would be cost-effective
over a 12-month time horizon.
TABLE 27 Costs of health-care resources used (not imputed)
Cost type
Surgisis anal fistula plug
(n= 87), mean (SD) (£)
Surgeon’s preference
(n= 90), mean (SD) (£)
Difference
p-value of t-test
Surgery-related costs 2306 (610) 1728 (502) 0.0000
Hospital-based costs due to readmissions 159 (412) 89 (363) 0.2330
Health and social services use 267 (777) 484 (1014) 0.1092
Total costs 2738 (1151) 2308 (1228) 0.0174
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TABLE 29 Total costs and QALYs by treatment arm (deterministic, non-imputed)
QALYs Surgisis anal fistula plug (n= 87) Surgeon’s preference (n= 90)
Total QALYs (SD) 0.829 (0.174) 0.790 (0.212)
Total cost, £ (SD) 2738 (1151) 2308 (1228)
TABLE 28 EuroQol-5 Dimensions, three-level version, index scores at baseline and follow-ups, and total QALYs by
treatment arm (not imputed)
Time point Surgisis anal fistula plug (n= 87) Surgeon’s preference (n= 90)
Difference p-value
of t-test
Baseline
Mean (SD) 0.810 (0.238) 0.750 (0.220) 0.0818
Median 0.796 0.796
Minimum–maximum –0.594 to 1.000 –0.016 to 1.000
6 weeks
Mean (SD) 0.791 (0.222) 0.780 (0.229) 0.7330
Median 0.796 0.796
Minimum–maximum 0.082 to 1.000 –0.181 to 1.000
6 months
Mean (SD) 0.837 (0.210) 0.775 (0.287) 0.0998
Median 0.883 0.796
Minimum–maximum 0.082 to 1.000 –0.239 to 1.000
12 months
Mean (SD) 0.856 (0.195) 0.836 (0.236) 0.5372
Median 1.000 0.924
Minimum–maximum –0.181 to 1.000 –0.331 to 1.000
Total QALYs
Mean (SD) 0.829 (0.174) 0.790 (0.212) 0.1820
Median 0.852 0.832
Minimum–maximum 0.043 to 1.000 –0.102 to 1.000
TABLE 30 Probabilistic cost-effectiveness results (non-imputed)
Strategy
Total cost,
mean (SD) (£)
Incremental
cost, mean
(SD) (£)
QALY,
mean (SD)
Incremental
QALY, mean
(SD)
ICER,
mean (SD)
(£/QALY)
Incremental
net benefit,
mean (SD) (£)
Surgeon’s
preference
2308 (129) 0.790 (0.022)
Surgisis anal
fistula plug
2738 (123) 430 (178) 0.829 (0.183) 0.039 (0.029) 10,993 (478,666) 352 (622)
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Cost-effectiveness results (imputed)
Considering the imputed data values, the probabilistic cost-effectiveness results for the imputed data are
shown in Table 27. There are only minor differences in the mean costs and mean QALYs for the surgeon’s
preference group and the fistula plug group compared with the non-imputed data. The ICER is £17,279 per
QALY, which is still below the NICE acceptance threshold of £20,000 per QALY, and the incremental net
benefit is £71.
However, given the differences in the mean utility values at baseline, as informed by the EQ-5D-3L (see
Table 24), the results were adjusted by baseline EQ-5D-3L values. Table 31 shows that when adjusting for
baseline EQ-5D-3L values the ICER is £32,400, which is above the NICE acceptance threshold of £20,000
per QALY.
The uncertainty of the cost-effectiveness estimate for the imputed data with baseline adjustment in the
cost-effectiveness plane is shown graphically in Figure 11, using bootstrapping with 1000 iterations. For
each bootstrap iteration, a new imputed data set was created, leading to 1000 incremental cost and
incremental QALY estimates being produced.
The majority of iterations have a positive incremental cost, which indicates that the fistula plug is very likely
to be more costly than the surgeon’s preference. Moreover, the majority of iterations also see a positive
incremental QALY estimate, which suggests that the fistula plug is likely to be more effective than
surgeon’s preference in terms of QALYs gained. Finally, it is notable that for all 1000 iterations the fistula
plug was always more expensive than surgeon’s preference.
TABLE 31 Cost-effectiveness results (UK NHS and PSS perspective, probabilistic, imputed)
Strategy
Total cost,
mean (SD) (£)
Incremental
cost, mean
(SD) (£)
QALY,
mean (SD)
Incremental
QALY, mean
(SD)
ICER, mean (SD)
(£/QALY)
Incremental
net benefit,
mean (SD)
Surgeon’s
preference
2297 (118) 0.800 (0.021)
Surgisis anal
fistula plug
2750 (112) 453 (163) 0.826 (0.018) 0.026 (0.027) 17,279 (1,168,154) 71 (578)
Adjusted
baseline
EQ-5D-3L
32,400 –168
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FIGURE 11 Cost-effectiveness plane showing the incremental cost and QALYs for the fistula plug group compared
with the surgeon’s preference group from the bootstrap analysis of the imputed data adjusted for baseline
EQ-5D-3L (mean values also shown).
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The cost-effectiveness acceptability curve showing the probability that the fistula plug is cost-effective is
presented in Figure 12 across a range of threshold values of WTP for a single QALY. The probability that
the fistula plug is cost-effective is approximately 35–45% across the broader NICE acceptance threshold of
£20,000–30,000 per QALY. At WTP thresholds for a QALY above £30,000, the probability that the fistula
plug will be cost-effective gradually increases, plateauing at approximately 65%.
Economic model
Given the lack of secondary sources to inform patient outcomes beyond 12 months, no economic
modelling was undertaken.
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FIGURE 12 Cost-effectiveness acceptability curve showing the probability that the fistula plug will be cost-effective
compared with surgeon’s preference across different WTP values for a single QALY, using the bootstrap analysis of
the imputed data adjusted for the baseline EQ-5D-3L.
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Chapter 4 Discussion
The FIAT is the largest known RCT trial investigating modern techniques for the treatment of trans-sphincteric fistula-in-ano. It provides important data on a recently introduced technology, the Surgisis anal
fistula plug, which combines ease of application with the promise of minimal compromise to anal sphincter
function and, therefore, maximal preservation of continence. However, the fistula plug comes with uncertainty
regarding its efficacy and whether or not the potential benefits justify the additional cost of the device.
In addition to answering the above questions, the FIAT provides valuable information about current
treatment preferences for fistula treatment in the UK NHS (cutting seton, fistulotomy, advancement flap
and LIFT procedure), along with an assessment of their efficacy and cost-effectiveness. The primary outcome
measure, HRQoL, was chosen to reflect the impact of the various surgical techniques from a patient
perspective; however, important secondary outcomes include not just the clinical rates of fistula healing but
also radiological evidence of fistula healing, a feature unique to the FIAT that provides additional credence
to the results.
The FIAT opened to recruitment in May 2011 with an anticipated accrual rate of 15 patients per month
over 3 years, based on published incidence rates for trans-sphincteric fistulas of 1–2 people per 10,000
of the population.1,2 The trial closed to recruitment in March 2016 having reached a revised recruitment
target of 304 patients. The primary reason for the slower than expected recruitment is reflected in the
CONSORT diagram (see Figure 3), with 1355 participants being screened for eligibility (a recruitment rate
of approximately 1 in every 20 patients screened). By far the most common reason for ineligibility (76%)
was the fistula morphology as assessed by a combination of clinical examination (EUA) and radiological
assessment (baseline MRI). Clinical examination has previously been relied on to characterise fistula
morphology, but is notoriously inaccurate and highly influenced by the experience of the individual
surgeon.36 MRI has been shown to improve the diagnostic accuracy for fistula-in-ano,22 although its
routine use in the treatment algorithm for all anal fistulas is debated. The fistulas investigated in FIAT were
all complex, by nature of their trans-sphincteric anatomy, and baseline MRI was mandatory prior to
randomisation into the trial. Although most surgeons reviewed the MRI report, only around a half viewed
the MRI scans, despite the fact that the MRI findings were felt to influence the surgical approach in around
16% of cases. The compulsory use of baseline MRI adds rigour to our analyses, but highlights the fact
that fistulas considered to be trans-sphincteric can be more or less complex than apparent on clinical
examination alone. Our data comparing EUA with MRI assessment revealed a concordance rate of only
34%, with MRI picking up more complex fistula disease or additional findings that justifies its use as a
first-line investigation in all but the simplest of fistulas.
The baseline data show that the randomisation process in the FIAT produced a balanced proportion of
participants in terms of pre-existing incontinence symptoms and risk factors for fistula healing. In particular,
smokers, previous history of fistula surgery and fistula characteristics, factors that are considered to
predispose to worse outcomes following fistula surgery,37–39 were equally represented in the fistula plug
and surgeon’s preference groups. The baseline data also emphasise the difficulties with fistula surgery, in
that it is infrequently amenable to a single intervention, but often multiple attempts are required to affect
a cure. In the FIAT, 45% of participants had undergone a previous attempt at fistula eradication, with
60% suffering from chronic sepsis or recurrent fistulous disease.
The FIAT cohort is typical of the patient population suffering from fistula-in-ano, the majority of whom are
healthy (ASA I) patients aged between 30 and 60 years, among whom there is a slight predominance of
men. The young age of this affected population highlights the importance of finding effective treatments
in this active, working population. Incontinence rates in this patient population are low and any disturbance
of anal continence as a result of fistula treatment is likely to have a lifetime effect on physical and mental
well-being and productivity, hence the importance attached to the preservation of continence when
considering the efficacy of any fistula treatment. Although the St Mark’s incontinence scores in the FIAT
cohort were higher than expected in comparison with an age-matched group without fistulous disease,
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they were generally low, indicating mild incontinence symptoms associated with the presence of a fistula. If
anything, the rates of baseline incontinence symptoms reported in the FIAT are likely to be an overestimate,
with symptoms, such as incontinence to gas, alteration in lifestyle and the wearing of pads, often attributable
to the active fistula tract rather than true compromise to the anal sphincter mechanism.
In terms of the primary outcome measure, FIQoL at the 12-month follow-up, the FIAT found a marginal
improvement in QoL in both the fistula plug group and the surgeon’s preference group, but no statistically
significant difference between the groups (a finding that was reflected in all four domains of the FIQoL
evaluation). Adamina et al.,40 in a prospective cohort trial of 46 patients undergoing fistula plug treatment,
reported a more marked improvement in QoL, as measured by the Short Form questionnaire-36 items
version 2. Bondi et al.,41 in a randomised trial comparing the fistula plug with advancement flap, found an
improvement in QoL at 3 months, but no difference between the two techniques. The per-protocol analysis
of the primary end point did not alter the findings, indicating that non-adherence to the randomisation
allocation failed to have a material influence on the results. The prespecified subgroup analyses of the four
randomisation minimisation factors (i.e. age, ASA grade, type of surgery, fistula extensions) also failed to
demonstrate an influence on the primary outcome measure, which might be an unexpected finding given
the perception that increasing age and ASA grade tend to be associated with poorer wound healing, and
that certain techniques for fistula eradication (cutting seton and fistulotomy) are associated with high rates
of incontinence compared with so-called sphincter-sparing techniques (LIFT procedure).
Fistula healing rates in both the fistula plug group and the surgeon’s preference group were at the
lower end of the spectrum reported in the literature. Overall, the fistula healing rates reported in the FIAT
might be viewed as disappointing, particularly when viewed against the literature, which is dominated by
single-institution studies. However, in comparison with the other randomised trials evaluating the fistula
plug, the results of the FIAT are consistent. In a randomised comparison of 94 patients treated with the
fistula plug or advancement flap, the recurrence rate at 12 months was 66% with the fistula plug and
38% with the advancement flap,41 whereas in a similar randomised comparison of the fistula plug against
advancement flap, involving 60 patients, the recurrence rates were 71% and 52% with the fistula plug
and advancement flap, respectively.42 Similarly, low rates of fistula healing using the fistula plug were
reported in a non-randomised, multicentre prospective trial of 90 patients, with fistula healing at
12 months reported in 49% of patients.43 Several systematic reviews and meta-analyses have now been
published, documenting healing rates with the fistula plug varying between 35% and 87%, with higher
rates in patients with single fistula tracts than in those with multiple fistula tracts.18,19,44 In the FIAT there
was no statistically significant difference between the fistula plug and surgeon’s preference groups at any
of the time points, with only around one-third of fistulas healed by 6 weeks and just over half healed by
12 months. When the FIAT cohort was analysed for the influence of randomisation minimisation factors
(i.e. age, ASA grade, type of surgery, fistula extensions) on healing rates, no significant differences were
found. Again, this might seem somewhat surprising, given that age and ASA grade are believed to
influence wound healing and the presence of more extensive disease (fistula extensions) is thought to
predispose to fistula recurrence/persistence.
Although care has to be taken when drawing conclusions from our subgroup analysis of fistula healing by
procedure undertaken, owing to the low numbers in each treatment group, some interesting observations
emerge. The most effective surgical operation appeared to be fistulotomy [12/16 (75%) fistulas healed at
12 months], whereas the LIFT procedure, perhaps surprisingly in consideration of the literature, performed
worst, with only 16 (29%) of 55 fistulas and 21 (45%) of 50 fistulas healed at 6 weeks and 12 months,
respectively. By comparison, success rates reported in the literature, in terms of fistula healing, range between
70% and 80%,16,45,46 although most studies report only short-term follow-up. The cutting seton healed few
fistulas (7/47 fistulas, 15%) at 6 weeks, but 27 (66%) of 41 fistulas by 12 months, in keeping with its mode of
action, which is to produce a slow division of the included sphincter muscle. Although many UK surgeons are
critical of the cutting seton, because of the fear of incontinence, encouraging results have been reported with
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little consequence on continence function.47 The advancement flap healed 11 (52%) of 21 fistulas by 6 weeks,
with a similar percentage (9/17 fistulas, 53%) remaining healed at 12 months. This is in keeping with reported
rates in the literature, with one retrospective review reporting fistula healing rates of 63% with advancement
flap, compared with 32% with the fistula plug, at a mean follow-up of 56 weeks,48 and an other trial reporting
healing rates at 12 weeks of 59.3%, 60.4% and 32.6% with the use of the fistula plug, advancement flap and
cutting seton, respectively.49
The results from the FIAT were obtained by rigorous data collection as part of a RCT undertaken across
40 NHS hospitals and provide a fascinating insight into the efficacy of fistula surgery. The poor results of
fistula surgery, regardless of surgical technique, are supported by the high percentage of FIAT participants
who at baseline reported having previously undergone a fistula operation (overall 45% of participants) and
the high rates of surgical reintervention reported at the 12-month follow-up (fistula plug group, n/N = 28/124,
23%; surgeon’s preference group, n/N = 27/121, 22%). Many of the surgical reinterventions were for
septic complications secondary to fistula recurrence. It is known that many factors affect the outcomes of
fistula surgery, including the characteristics of the fistula,50 the surgical technique used and the centre/surgeon
undertaking the operation.39,51 With specific reference to the technique of fistula plug insertion, there is
evidence that the use of a prior draining seton does not affect healing rates, although the length of the
fistula tract may be a determining feature.50 Further in-depth analysis of the FIAT data set will undoubtedly
give more insights into current practice and outcome variability within the UK NHS.
Although the long-term results of fistula surgery in terms of healing rates are poor, the surgical procedures
themselves impart a low risk of morbidity in the early postoperative period, and repeated interventions in
an attempt to eradicate the disease would appear to be justified. The main complication related to any
type of fistula surgery appears to be protracted pain, which was the most reported complication up to
6 months’ follow-up (fistula plug group, n/N = 14/27, 52%; surgeon’s preference group, n/N = 7/27, 26%).
By the 12-month follow-up, septic complications appeared to be more problematic, although unexpected
pain continued to be represented, accepting that there is overlap in the reporting of these two symptoms
given that sepsis is frequently accompanied by pain. The only significant difference in the complications
rates between the two groups in the FIAT was observed at 6 weeks and was probably influenced by the
higher rate of unexpected pain in the fistula plug group than in the surgeon’s preference group (fistula
plug group, n/N = 32/49, 65%; surgeon’s preference group, n/N = 9/25, 36%; p = 0.002). This did not
appear to be due to a higher rate of sepsis in the fistula group. Rather, it might be related to the method
of securing the fistula plug, by stitching it to the internal anal sphincter, causing sphincter spasm, or a
lower threshold for reporting pain in participants who might have perceived the fistula plug to be a
minimally invasive, low-pain procedure. A complication specific to the fistula plug is plug extrusion early in
the postoperative period, which is reported to occur in 10–15% of cases.18,44,52,53 Despite our best efforts
to standardise the method of fistula plug insertion in line with best practice techniques, including hands-on
proctoring of investigators for the first three cases and the use of instruction videos, the plug extrusion
rate in the FIAT remained at 16%. Further research into fistula plug fixation within the high-pressure anal
canal is required to reduce the rate of plug extrusion. If this can be achieved, it might have a substantial
impact on the overall healing rates achievable with the plug.
Preservation of continence is of paramount importance when considering surgery for fistula disease. On
average, the St Mark’s incontinence scores in both the fistula plug group and the surgeon’s preference
group were low at baseline. There appeared to be a numerical improvement in incontinence scores over
time in both groups, which might reflect a positive change in certain symptoms (e.g. alteration in lifestyle,
wearing a pad) associated with anal fistula, rather than a true improvement in anal continence. It is
perhaps surprising that the surgeon’s preference group did not perform worse than the fistula plug group,
given that it allowed the use of techniques (i.e. fistulotomy, advancement flap, cutting seton) known to
injure the anal sphincter mechanism.
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Given the overall lack of significant differences in efficacy and safety of the fistula plug, compared with other
techniques for fistula treatment, the cost-effectiveness analysis is particularly important when considering
widespread uptake of the plug within the UK NHS. Using EQ-5D to generate QALYs, a number of alternative
results were obtained based on different approaches to the analysis of the data. The complete-case analysis
showed that the fistula plug group experienced a slightly higher QALY gain than the surgeon’s preference
group (0.829 vs. 0.790). The mean cost was higher in the fistula plug group than in the surgeon’s preference
group (£2738 vs. £2308), driven by the additional cost of the Surgisis anal fistula plug. Applying probabilistic
analysis to the complete data, the ICER was found to be £10,933 per QALY, indicating that the fistula plug
may be considered to be more cost-effective than surgeon’s preference, although the SD (478,666) indicates
the large uncertainty in this estimate. Using multiple imputation to increase the data set to 267 patients
and probabilistic sensitivity analysis, the fistula plug was again found to be more costly (£2750 vs. £2297)
and more effective (0.826 vs. 0.800 QALYs gained) compared with surgeon’s preference. In this case, the
ICER was £17,279, again suggesting that the fistula plug may be considered to be more cost-effective
than surgeon’s preference. However, when adjustment was made to account for differences in EQ-5D at
baseline, the ICER increased to £32,400, suggesting that the fistula plug may not be considered to be
cost-effective. Uncertainty in the results for the multiple imputed data adjusted for baseline EQ-5D suggests
that the fistula plug is 35–45% more likely than surgeon’s preference to be cost-effective at thresholds
of WTP for a QALY of £20,000–30,000. Thus, it can be concluded that the fistula plug may not be a
cost-effective approach to the treatment of patients with high trans-sphincteric fistulas.
In terms of taking these results forward, a key approach would be to implement an economic model to
examine how patient outcomes beyond the 1-year time horizon would impact on the conclusions drawn
from the cost-effectiveness analysis. However, in order to do this, information would be required to inform
the HRQoL of the patients beyond 1 year. At present, no such data are available and, consequently, in
the FIAT a sensible economic model was not possible. Hypothetically, if it were assumed that the EQ-5D
utility values collected at 12 months remained unchanged beyond that time, then it might be concluded
that the fistula plug would become increasingly cost-effective as time passes. However, there is little
evidence beyond the 12-month follow-up to justify this assumption. For example, a review in 2009
included 12 studies, all of which were small scale and had a median follow-up period of ≤ 12 months.18
More recent studies have provided no indication of the longer-term costs and effects; a systematic review
from 2015 identified no studies in which the follow-up period was longer than 14 months.54 A subsequent
review of another fistula plug (GORE® BIO-A®, Gore Medical, Newark, DE, USA) included one trial which
had follow-up ranging from 3 to 19 months; however, the median was only 5 months and the trial included
only 11 patients.53 Nevertheless, as data become available, modelling approaches could be implemented
to provide further insights to inform the cost basis for wider adoption of fistula plug technology.
Limitations
The limitations of the FIAT include the need to reduce the recruitment target because of the lower than
anticipated accrual rate. As alluded to above, this was partly due to a high exclusion rate, probably associated
with the mandatory use of baseline MRI and perhaps an overestimation in the literature about the true rate
of trans-sphincteric fistulas compiled in an era when MRI was not available. Despite a reduction in target
recruitment from 500 to 300 patients, the FIAT was still powered to detect a small to moderate difference
in the primary outcome (FIQoL). In addition, the original sample size calculation factored in a 20% dropout
rate, which did not materialise. Only 7 (2%) out of 304 participants were lost to follow-up and compliance
with follow-up data was extremely good. Given the lack of any convincing difference in FIQoL between the
fistula plug group and the surgeon’s preference group, it is unlikely that achieving the original sample size
of 400 patients would have altered the results. Similarly, the crossover of patients between the treatment
arms does not appear to have had a material influence on the results, as demonstrated by the per-protocol
analysis.
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The FIAT was an unblinded, parallel-group trial. It would obviously not have been possible to blind the
surgeons to the treatment allocation. Similarly, it would have been difficult to blind the participants, given
that some would have had an anodermal wound (LIFT procedure), whereas others did not (fistula plug and
advancement flap) and others would have had a seton protruding from the anal canal (cutting seton).
Likewise, blinding of the data collectors would have introduced problems in the collection of treatment-
specific information, such as the rate of fistula plug extrusion. Although non-blinding might have
introduced an element of bias, perhaps in patient reporting of postoperative pain, it is unlikely to have
affected the primary outcome, for which there was no observable difference between the treatment arms.
Strenuous attempts were made to standardise the technique for the placement of the fistula plugs,
including surgeon attendance at a mandatory training session, preceptorship with the first three procedures
undertaken and video instruction. This was undertaken in an attempt to eliminate any learning curve effect
associated with the fistula plug technique, which was probably small given that plug placement is a simple
procedure that is well within the skill set of the coloproctologists participating in the FIAT. Standardisation
was also considered to be important in reducing the occurrence of early fistula plug extrusion. Despite this,
plug extrusion was still reported in 16% of cases of the fistula plug, perhaps indicating an intrinsic problem
with the placement of prostheses within the high-pressure anal canal.
A criticism that could be levelled at the FIAT is the small number of patients recruited by several
participating sites. This probably reflects the relatively low incidence of trans-sphincteric, cryptoglandular
fistula-in-ano, but is mitigated to some degree by the simplicity of the fistula plug technique and the
associated short learning curve.
One of the strengths of the FIAT was in the mandatory use of MRI at baseline and the 12-month follow-up,
to overcome the recognised inaccuracies in relying solely on clinical examination to characterise fistulas and
assess healing. Although we achieved 100% success in obtaining baseline MRI, despite our best efforts we
were only able to obtain follow-up imaging for 73% of patients. This is probably still sufficient to obtain
reasonable data accuracy and certainly far exceeds, to our knowledge, any previous attempts to use
radiological imaging to obtain unequivocal evidence of fistula healing.
Conclusion
The FIAT failed to show a difference in the primary end point, FIQoL, between the fistula plug group and
the surgeon’s preference group at the 12-month follow-up. Reassuringly, there was a low rate of early
postoperative complications in both groups, indicating that fistula surgery generally carries a low level of
morbidity and, therefore, it is justified to perform repeat procedures in an attempt to eradicate the disease.
Similarly, it is reassuring to note that incontinence following fistula surgery is generally low, regardless of the
surgical technique, and perhaps this should not be used exclusively as a rationale to support the use of the
fistula plug. One of the stark highlights of the FIAT is the poor fistula healing rate obtained with all types of
fistula surgery. The procedures included in the surgeon’s preference group are those most widely practised
by colorectal surgeons in the UK. The results emphasise the inadequacies of current fistula surgery and the
need for further research into the underlying pathophysiology of the disease in order to design new, more
effective, therapies. Although alternative approaches to fistula eradication continue to be reported in the
literature, there is no convincing evidence that they offer any advantage over those evaluated in the FIAT.
Importantly, surgeons should learn to manage the expectations of patients suffering with fistula-in-ano,
stressing the high failure rates in terms of fistula healing and the need for multiple reinterventions if the aim
is to eradicate the disease. The FIAT has provided a health economics evaluation of the fistula plug in
comparison with other commonly used surgical techniques. On the basis of the results presented, the fistula
plug is more expensive than surgeon’s preference and more effective in terms of QALYs gained. Differences
in QALY gains are very small and uncertain in our analysis. Taking account of parameter uncertainty and
using some imputation to increase effective sample size, this study suggests that the fistula plug technology
is unlikely to be considered a cost-effective use of UK NHS resources.
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Recommendations for research
Further research might look at the long-term follow-up of the FIAT cohort to assess whether or not the
outcomes change with time. In particular, the lower rates of fistula healing as assessed by MRI, compared
with clinical evaluation, might manifest in further fistula recurrences in the future. As previously mentioned,
it would also be informative to develop an economic model to examine how patient outcomes beyond
the 1-year time horizon impact on the conclusions drawn from the cost-effectiveness analysis. Since the
completion of the FIAT, a number of new technologies have been proposed for the treatment of trans-
sphincteric fistula and it would be interesting to see if they offer any additional benefit.
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l Ms Arabis Oglesby, Research Nurse.
l Ms Karen Hogben, Research Nurse.
George Eliot Hospital NHS Trust (George Eliot Hospital)
l Mr Kalimuthu Marimuthu, PI and Lead Surgeon.
l Dr Amitabh Palit, Lead Radiologist.
l Ms Rosemary Musanhu, Lead Research Nurse.
l Ms Emma Brannan, Clinical Trials Co-ordinator.
Gloucestershire Hospitals NHS Foundation Trust (Cheltenham General
Hospital)
l Mr James Wheeler, PI and Lead Surgeon.
l Dr Richard Hopkins, Lead Radiologist.
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Heart of England NHS Foundation Trust (Birmingham Heartlands Hospital/
Good Hope Hospital)
l Mr Haney Youssef, PI and Lead Surgeon.
l Mr David McArthur, Consultant Surgeon.
l Dr Mark Goldstein, Lead Radiologist.
l Ms Linda Webber, Lead Research Nurse.
Homerton University Hospital NHS Foundation Trust (Homerton
University Hospital)
l Ms Tamzin Cuming, PI and Lead Surgeon.
l Dr Peter Boavida, Lead Radiologist.
l Ms Sophia Hans, Research Assistant.
Imperial College Healthcare NHS Trust (Charing Cross Hospital/St Mary’s
Hospital)
l Mr Gordon Buchanan, PI and Lead Surgeon (until October 2015).
l Mr George Reese, PI and Lead Surgeon (from October 2015).
l Mr Peter Dawson, Lead Radiologist.
l Ms Melloney Allnutt, Research Nurse.
l Ms Gillian Hornzee, Research Nurse.
l Ms Byiravey Pathmanathan, Research Nurse.
Mid Essex Hospital Services NHS Trust (Broomfield Hospital)
l Mr Toby Hammond, PI and Lead Surgeon.
l Dr Peng Lee, Lead Radiologist.
l Ms Joanne Topliffe, Lead Research Nurse.
The Royal Wolverhampton NHS Trust (New Cross Hospital)
l Mr Graham Williams, PI and Lead Surgeon.
l Dr Peter Li, Lead Radiologist.
l Ms Stella Metherell, Lead Research Nurse.
NHS Highland (Raigmore Hospital)
l Professor Angus Watson, PI and Lead Surgeon.
l Mr Michael Lim, Consultant Surgeon.
l Mr Kenneth Walker, Consultant Surgeon.
l Mr James Docherty, Consultant Surgeon.
l Dr Jason Walker, Lead Radiologist.
l Ms Kathleen Macleod, Lead Research Nurse.
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Norfolk and Norwich University Hospitals NHS Foundation Trust (Norfolk
and Norwich University Hospital)
l Mr Christopher Speakman, PI and Lead Surgeon.
l Dr Stuart William, Lead Radiologist.
l Ms Georgina Glister, Lead Research Nurse.
Nottingham University Hospitals NHS Trust (Queen’s Medical Centre)
l Professor John Scholefield, PI and Lead Surgeon.
l Mr Mike Robinson, Consultant Surgeon.
l Mr Ayan Banerjea, Consultant Surgeon.
l Dr William Dunn, Lead Radiologist.
l Ms Mandy Eyre, Lead Research Nurse.
Oxford University Hospitals NHS Foundation Trust (Churchill Hospital/
John Radcliffe Hospital)
l Mr Christopher Cunningham, PI and Lead Surgeon.
l Dr Andrew Slater, Lead Radiologist.
Poole Hospital NHS Foundation Trust (Poole Hospital)
l Mr Guy Nash, PI and Lead Surgeon.
l Dr David Tarver, Lead Radiologist.
Portsmouth Hospitals NHS Trust (Queen Alexandra Hospital)
l Miss Asha Senapti, PI and Lead Surgeon.
l Dr Anthony Higginson, Lead Radiologist.
l Ms Elizabeth Hawes, Research Nurse.
l Ms Sheeba Babu, Research Nurse.
l Ms Karen Flashman, Data Manager.
Royal United Hospitals Bath NHS Foundation Trust (Royal United
Hospitals Bath)
l Mr Michael Williamson, PI and Lead Surgeon.
l Dr Andrea Phillips, Lead Radiologist.
l Ms Joyce Katebe, Research Nurse.
l Ms Dawne Chandler, Research Nurse.
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
Sandwell and West Birmingham Hospitals NHS Trust (Sandwell General
Hospital)
l Miss Kathryn Gill, PI and Lead Surgeon.
l Dr Rosamund Donovan, Lead Radiologist.
l Ms Julie Colley, Lead Research Nurse.
l Ms Elzbieta Zulueta, Surgical Care Practitioner Colorectal/General Surgery.
South Tees Hospitals NHS Foundation Trust (The James Cook University
Hospital)
l Mr Douglas Atkin, PI and Lead Surgeon.
l Dr Sumeet Miranda, Lead Radiologist.
Southend University Hospital NHS Foundation Trust (Southend Hospital)
l Mr Bandipalyam Praveen, PI and Lead Surgeon.
l Mr Manoj Jacob, Speciality Doctor in Colorectal Surgery.
l Dr Saman Perera, Lead Radiologist.
l Ms Sharon Tysoe, Lead Research Nurse.
Southport and Ormskirk Hospital NHS Trust (Southport and Formby
District General Hospital)
l Dr Dimitri Artioukh, PI and Lead Surgeon.
l Dr Apam Chiphang, Lead Radiologist.
l Ms Anna Morris, Research Nurse.
l Ms Dawn Baker, Research Nurse.
St Helens and Knowsley Teaching Hospitals NHS Trust (Whiston Hospital)
l Mr Raj Rajaganeshan, PI and Lead Surgeon.
l Dr Kirsty Slaven, Lead Radiologist.
Taunton & Somerset NHS Foundation Trust (Musgrove Park Hospital)
l Ms Louise Hunt, PI and Lead Surgeon.
l Mr Paul Mackey, Consultant Surgeon.
l Dr Paul Burn, Lead Radiologist.
l Ms Jayne Foot, Lead Research Nurse.
Hillingdon Hospitals NHS Foundation Trust (Hillingdon Hospital)
l Mr Yasser Mohsen, PI and Lead Surgeon.
l Mr Alistair Myers, Consultant Surgeon.
l Dr Ziad Meer, Lead Radiologist.
l Miss Alex Diaz, Research Nurse.
l Ms Mariam Nasseri, Research Nurse.
l Ms Melinda Holden, Research Nurse.
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Ipswich Hospital NHS Trust (Ipswich Hospital)
l Mr James Pitt, PI and Lead Surgeon.
l Dr Simon Smith, Lead Radiologist.
l Ms Claire Swann, Lead Research Nurse.
Leeds Teaching Hospitals NHS Trust (St James’s University Hospital/Leeds
General Hospital)
l Professor David Jayne, PI and Lead Surgeon.
l Dr Damian Tolan, Lead Radiologist.
l Ms Catherine Moriarty, Lead Research Nurse.
The Mid Yorkshire Hospitals NHS Trust (Pinderfields General Hospital/
Dewsbury and District Hospital)
l Mr Chris Macklin, PI and Lead Surgeon.
l Dr Katherine Naik, Lead Radiologist.
l Ms Stephanie Lupton, Lead Research Nurse.
Royal Liverpool and Broadgreen University Hospitals NHS Trust
(The Royal Liverpool University Hospital)
l Mr Paul Rooney, PI and Lead Surgeon.
l Dr Mark Hughes, Lead Radiologist.
l Dr Priya Healey, Lead Radiologist.
University Hospitals Birmingham NHS Foundation Trust (Queen Elizabeth
Hospital Birmingham)
l Mr Nigel Suggett, PI and Lead Surgeon.
l Professor Dion Morton, Consultant Surgeon.
l Dr Deborah Tattersall, Lead Radiologist.
l Dr Manijeh Ghodds, Data Contact.
University Hospitals Bristol NHS Foundation Trust (Bristol Royal
Infirmary)
l Mr Michael Thomas, PI and Lead Surgeon.
l Dr Huw Roach, Lead Radiologist.
l Dr Mark Callaway, Lead Radiologist.
l Ms Rebecca Houlihan, Research Nurse.
l Ms Karen Bobruk, Research Nurse.
l Ms Catherine Phillpott, Research Nurse.
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University Hospitals of Leicester NHS Trust (Leicester General Hospital)
l Mr Baljit Singh, PI and Lead Surgeon.
l Dr Ratan Verma, Lead Radiologist.
Wirral University Teaching Hospital NHS Foundation Trust (Arrowe Park
Hospital)
l Mr Liviu Titu, PI and Lead Surgeon.
l Dr Nicholas Day, Lead Radiologist.
l Ms Helyn Evans, Lead Research Nurse.
Yeovil District Hospital NHS Trust (Yeovil District Hospital)
l Mr Nader Francis, PI and Lead Surgeon.
l Dr Charles Hopkins, Lead Radiologist.
l Mrs Joanna Alison, Research Nurse.
l Ms Alison Lewis, Research Nurse.
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Appendix 2 Site recruitment
TABLE 32 Site recruitment
Site name Date site opened
Date first
participant
randomised
Date last
participant
randomised
Number of
participants
randomised
Leeds Teaching Hospitals NHS Trust
(St James’s University Hospital/Leeds
General Infirmary)
1 November 2010 4 July 2011 26 February 2016 28
Dorset County Hospital NHS
Foundation Trust (Dorset County
Hospital)
17 May 2011 24 May 2011 5 February 2015 9
Royal Devon and Exeter NHS
Foundation Trust (Royal Devon and
Exeter Hospital)
17 May 2011 – – 0
Sandwell and West Birmingham
Hospitals NHS Trust (Sandwell
General Hospital)
31 May 2011 7 December 2011 11 July 2014 16
Portsmouth Hospitals NHS Trust
(Queen Alexandra Hospital)
17 June 2011 7 February 2012 18 February 2016 20
Southport and Ormskirk Hospital
NHS Trust (Southport and Formby
District General Hospital)
28 June 2011 11 January 2013 24 January 2014 3
Ipswich Hospital NHS Trust (Ipswich
Hospital)
1 July 2011 21 October 2013 10 October 2014 2
Nottingham University Hospitals NHS
Trust (Queen’s Medical Centre)
13 July 2011 27 September 2011 2 March 2016 20
South Tees Hospitals NHS
Foundation Trust (The James Cook
University Hospital)
21 July 2011 5 November 2012 23 December 2014 2
North Devon Healthcare NHS Trust
(North Devon District Hospital)
25 July 2011 – – 0
Norfolk and Norwich University
Hospitals NHS Foundation Trust
(Norfolk and Norwich University
Hospital)
28 July 2011 16 May 2012 22 October 2015 6
Croydon Health Services NHS Trust
(Croydon University Hospital)
23 August 2011 9 May 2012 21 March 2014 5
University Hospitals of Leicester NHS
Trust (Leicester General Hospital)
24 August 2011 21 January 2013 22 August 2014 6
University Hospitals Bristol NHS
Foundation Trust (Bristol Royal
Infirmary)
6 October 2011 26 January 2012 29 January 2015 9
Wirral University Teaching Hospital
NHS Foundation Trust (Arrowe Park
Hospital)
14 October 2011 6 January 2012 19 June 2015 7
Poole Hospital NHS Foundation Trust
(Poole Hospital)
24 October 2011 29 November 2011 29 November 2011 1
continued
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TABLE 32 Site recruitment (continued )
Site name Date site opened
Date first
participant
randomised
Date last
participant
randomised
Number of
participants
randomised
Cardiff & Vale University Health
Board (Llandough University
Hospital/University Hospital of Wales)
26 October 2011 10 April 2012 6 October 2015 13
University Hospitals Birmingham NHS
Foundation Trust (Queen Elizabeth
Hospital Birmingham)
1 November 2011 22 May 2012 14 January 2016 7
County Durham and Darlington NHS
Foundation Trust (University Hospital
of North Durham)
17 November 2011 – – 0
Gloucestershire Hospitals NHS
Foundation Trust (Cheltenham
General Hospital)
2 March 2012 28 January 2013 8 April 2013 4
Chesterfield Royal Hospital NHS
Foundation Trust (Chesterfield Royal
Hospital)
2 March 2012 30 July 2012 1 December 2015 8
Central Manchester University
Hospitals NHS Foundation Trust
(Manchester Royal Infirmary)
2 March 2012 11 March 2013 29 January 2016 17
Royal Liverpool and Broadgreen
University Hospitals NHS Trust (The
Royal Liverpool University Hospital)
2 March 2012 18 July 2013 2 September 2015 2
University Hospitals of Coventry and
Warwickshire NHS Trust (University
Hospital Coventry and Warwickshire)
2 March 2012 – – 0
South Warwickshire NHS Foundation
Trust (Warwick Hospital)
2 March 2012 – – 0
NHS Grampian (Aberdeen Royal
Infirmary)
21 March 2012 – – 0
NHS Highland (Raigmore Hospital) 22 March 2012 30 August 2012 24 February 2016 8
The Mid Yorkshire Hospitals NHS
Trust (Pinderfields General Hospital/
Dewsbury and District Hospital)
22 March 2012 4 December 2012 23 September 2015 5
Calderdale and Huddersfield NHS
Foundation Trust (Huddersfield Royal
Infirmary)
27 March 2012 4 May 2012 1 March 2013 3
Aneurin Bevan University Health
Board (Royal Gwent Hospital)
17 April 2012 – – 0
Aneurin Bevan University Health
Board (Nevill Hall Hospital)
17 April 2012 3 February 2014 3 February 2014 1
Southend University Hospital NHS
Foundation Trust (Southend
Hospital)
18 May 2012 1 August 2012 18 February 2016 32
Frimley Health NHS Foundation Trust
(Wexham Park Hospital)
15 August 2012 – – 0
Aintree University Hospital NHS
Foundation Trust (Aintree University
Hospital)
1 October 2012 – – 0
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
TABLE 32 Site recruitment (continued )
Site name Date site opened
Date first
participant
randomised
Date last
participant
randomised
Number of
participants
randomised
Barking, Havering and Redbridge
University Hospitals NHS Trust
(Queen’s Hospital)
3 October 2012 18 March 2013 10 March 2015 2
Royal United Hospitals Bath NHS
Foundation Trust (Royal United
Hospitals Bath)
22 January 2013 26 February 2014 29 February 2016 8
Salford Royal NHS Foundation Trust
(Salford Royal Hospital)
13 March 2013 – – 0
Yeovil District Hospital NHS Trust
(Yeovil District Hospital)
28 March 2013 4 October 2013 11 February 2015 2
Burton Hospitals NHS Foundation
Trust (Queen’s Hospital Burton)
3 June 2013 3 June 2013 3 August 2015 10
Hillingdon Hospitals NHS Foundation
Trust (Hillingdon Hospital)
5 June 2013 8 August 2014 24 November 2015 2
Heart of England NHS Foundation
Trust (Birmingham Heartlands
Hospital/Good Hope Hospital)
30 August 2013 21 October 2013 30 June 2015 4
Taunton & Somerset NHS
Foundation Trust (Musgrove Park
Hospital)
22 October 2013 3 February 2014 11 December 2015 11
Imperial College Healthcare NHS
Trust (Charing Cross Hospital/St
Mary’s Hospital)
15 November 2013 12 February 2014 4 February 2015 4
Oxford University Hospitals NHS
Foundation Trust (Churchill Hospital/
John Radcliffe Hospital)
27 January 2014 12 June 2014 29 February 2016 8
The Royal Wolverhampton NHS Trust
(New Cross Hospital)
10 February 2014 18 January 2016 18 January 2016 1
St Helens and Knowsley Teaching
Hospitals NHS Trust (Whiston
Hospital)
1 April 2014 19 May 2014 19 May 2014 1
Homerton University Hospital NHS
Foundation Trust (Homerton
University Hospital)
21 May 2014 15 September 2014 10 March 2016 6
Mid Essex Hospital Services NHS
Trust (Broomfield Hospital)
12 June 2014 19 June 2014 7 August 2015 5
Ashford and St Peter’s Hospitals NHS
Foundation Trust (St Peter’s Hospital)
12 June 2014 9 January 2015 5 October 2015 3
George Eliot Hospital NHS Trust
(George Eliot Hospital)
1 December 2014 23 December 2014 13 April 2015 3
North Bristol NHS Trust (Frenchay
Hospital/Southmead Hospital)
10 August 2015 – – 0
North Cumbria University Hospitals
NHS Trust (Cumberland Infirmary)
18 September
2015
– – 0
East Lancashire Hospitals NHS Trust
(Royal Blackburn Hospital)
18 September
2015
– – 0
Total 53 (sites) 40 (sites) – 304
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Appendix 3 Data completeness
TABLE 33 Data completeness
Data form
Surgisis anal fistula plug (N= 152) Surgeon’s preference (N= 152)
Expected, n Received, n (%) Expected, n Received, n (%)
Baseline data form 152 151 (99) 152 150 (99)
Radiology MRI form
Baseline 152 152 (100) 152 152 (100)
Follow-up 146 110 (75) 146 112 (77)
Intraoperative form 150 148 (99) 149 147 (99)
Postoperative form 148 147 (99) 147 144 (98)
Follow-up
6 weeks 149 142 (95) 148 137 (93)
6 months 147 129 (88) 147 129 (88)
12 months 146 124 (85) 146 122 (84)
EQ-5D-3L
Baseline 152 139 (91) 152 134 (88)
6 weeks 149 131 (88) 148 127 (86)
6 months 147 126 (86) 147 130 (88)
12 months 146 127 (87) 146 127 (87)
FIQoL
Baseline 152 139 (91) 152 134 (88)
6 weeks 149 128 (86) 148 127 (86)
6 months 147 125 (85) 147 129 (88)
12 months 146 126 (86) 146 128 (88)
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Appendix 4 Per-protocol analysis of the Faecal
Incontinence Quality of Life questionnaire by
treatment group
The per-protocol analysis failed to show any statistical difference in FIQoL by treatment group at any ofthe follow-up time points and, therefore, did not change the interpretation of the main ITT analysis.
TABLE 34 Per-protocol analysis of the FIQoL questionnaire, by treatment group
FIQoL domain
Surgisis anal fistula
plug, mean (SD, n)
Surgeon’s preference,
mean (SD, n)
Mean difference
(95% CI) p-value
Treatment by
time, p-value
FIQoL: lifestyle
Baseline 3.46 (0.75, 130) 3.35 (0.82, 136) 0.09 (–0.04 to 0.21) 0.17 0.54
6 weeks 3.54 (0.71, 123) 3.40 (0.83, 129)
6 months 3.59 (0.72, 118) 3.48 (0.78, 132)
12 months 3.63 (0.67, 120) 3.52 (0.78, 132)
FIQoL: coping/behaviour
Baseline 3.33 (0.73, 130) 3.14 (0.87, 136) 0.15 (0.01 to 0.28) 0.03 0.12
6 weeks 3.45 (0.72, 123) 3.16 (0.89, 129)
6 months 3.46 (0.78, 118) 3.29 (0.91, 132)
12 months 3.45 (0.82, 120) 3.31 (0.86, 131)
FIQoL: depression/self-perception
Baseline 3.05 (0.78, 124) 2.99 (0.79, 125) 0.13 (–0.02 to 0.28) 0.08 0.46
6 weeks 3.18 (0.75, 111) 3.01 (0.85, 121)
6 months 3.25 (0.76, 109) 3.15 (0.91, 120)
12 months 3.31 (0.82, 110) 3.19 (0.87, 122)
FIQoL: embarrassment
Baseline 3.26 (0.81, 124) 3.09 (0.86, 125) 0.17 (–0.001 to 0.34) 0.051 0.02
6 weeks 3.39 (0.81, 111) 3.08 (0.92, 120)
6 months 3.37 (0.85, 109) 3.27 (0.89, 121)
12 months 3.40 (0.87, 111) 3.22 (0.95, 122)
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